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The search for an effective cine for cancer has led to
a great deal of research in many fields. .vith increasing Knowledge
of cellular metabolism it has been possible to devise drugs in an
attempt to interfere with certain metabolic reactions which will
bring about the oenth of the malignant cell. Of particular
interest has bean recent progress concerning the elucidation of
the nature, function and synthesis of the genetic material of the
cell, deoxyribonucleic acid (DNA) • Tha biosynthetic pathways
involved in the synthesis of DNA are now known in considerable
detail and attempts have been made to interfere with certain of
the essential reactions involved. It was tire purpose of this
work to investigate more fully some of the reactions involved in
the biosynthesis of the thymine component of DMA and to elucidate
the mechanism of action of the thymidine analogue, iododeoxyuxldine,
which was known to inhibit its synthesis. luring the course of
the investigation, iododeoxyeytidine was synthesised. This
compound is closely related to lodododeoxyuridine and differs from
it only by the presence of an amino group in lieu of an oxygen in
position 6 of the pyriiaidine ring and following ensyaic destination,
the compound is converted into iododeoxyvxddine• Investigations
were performed with iododeoxyoytidine in ah attempt to assess tire
comparative effectiveness of this compound and iodooeoxyurioine as
inhibitors of the synthesis of the thymine component of DM.
The antimetabolites under study were both synthesised for
(-)
the first time in the department of rhanaacology at Yale University
and leave of absence from the University of dinburgh was granted
to m for one year in order that I might carry out experimental
studies in that department. luring that time 1 was working under
the close supervision of Dr. ff.H. Prusoff and for the many
kindnesses shown to me, by both Dr. Prusoff end toe head of the
department, Professor A.D. $eloh, I am deeply grateful.
The author wishes to express his thanks to Dr. K.H. Cirdwood
on whose suggestion this thesis was initiated and whose encouragement
and advice during the preparation of the manuscript have been
invaluable.
Financial support during this period was provided by a





Deoxyribonucleic acid (DNA) exists in nature as
deoxyrlbonucleoprotein (DNP) complexes. Both DNA and ribonucleic
acid (RNA) are normal constituents of all cells both plant and
animal, the DNA being confined to the nucleus, whereas ENA is found
in addition in the cytoplasm, MA is a large polymer with a
molecular weight of approximately 6,000,000. Studies with the
electron microscope and X-ray diffraction photographs induced
Watson and Crick (1953) to postulate that the atruetion of the
DNA molecule is a double helix consisting of two strands. There
are two spirally rising chains winding around the same axis made up
of phosphate groups and sugar moleoulea and these are linked by a
series of horisontal members, like steps, consisting essentially
of four bases, adenine, thymine, guanine and cytosine, arranged in
pairs. By making a scale model they were able to show that the
bases could fit only if they were arranged in pairs of one purine
and one pyrimidine, the purine adenine and the pyrimidine thymine
constituting one pair; while guanine and cytosine make up the
second pair. The bases are held together by hydrogen bonding and
it has been suggested that the sequence of the pairs along the chain
may govern the characteristics of the cell (Crick et al, 1961),
Before a cell can undergo mitotic division, the chromoaones,
with their genes, must replicate and since these are composed of
DNP it follows that new DNA synthesis must occur. Interference with
any of the reactions essential for the synthesis of DNA should
therefore inhibit the reproductive capacity of the cells. Of the
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four bases which are commonly found in DNA, thymine is the only
one unique to UNA, the other three, together with uracil being
found also in KNA. For this reason a good deal of attention has
been attracted towards the inhibition of the synthesis of the
thymine component of DNA and hence of DNA itself. Although other
approaches to the problem have been made, it is this one with whioh
this thesis is mainly concerned.
NUCLEIC ACID BASES AND THEIR DERIVATIVES.
The structure of the component parts of the nucleic acid
molecule is of interest# Complete hydrolysis yields pyrimidine
and purine bases# a sugar component and phosphoric acid. Partial
hydrolysis yields compounds known as nucleosides and nucleotides.
Pyrimidine bases are ail derivatives of the parent compound
pyrimidine and the structure of the main ones are shown in figure 1.
Cytosine and thymine are found in DNA but in KNA uracil replaces
thymine. There are some minor exceptions to this rule, however,
i
and thymine may be found in small amounts in the RNA of certain
microorganisms (Littlefield and Dunn, 1958). 5-methylcytosine may
also occur in small quantities in DNA from various sources (Davidson,
I960).
Purine bases are derived from the parent compound which is formed by
the fusion of a pyrimidine and an imidazole ring. Adenine and guanine
are the two main ones and both are found in KNA and DNA. Derivatives




























Diagram showing the structure of pyrimidine and soma of the
more common pyrimidine bases*
4.
Nucleosides.
A purine or pyrimidine base may be condensed with a pentose
or deoxypentose sugar to form a nucleoside. Thus thymine condenses
with deoxyribose to form thymidine and uracil condenses with ribose to
form uridine and with deoxyribose to form deoxyuridine.
The sugar component of RNA from every source so far tested
has been shown to be D-ribose and it is now widely assumed that the
pentose of ENA is always in this form.
From all mammalian and almost all other sources of DNA
investigated the sugar present has been shown to be D-deoxyribose
but glucose occurs glycosidioally linked to hydroxymethyl oytosine
in the DNA from certain strains of bacteriophage.
Nucleotides.
The nucleotides are phosphoric esters of the nucleosides.
Those derived from ribose nucleosides may be called ribonucleotides
and those derived from deoxyribonucleosides are deoxyribonucleotides.
The ribose nucleosides have three free hydroxyl groups and therefore
three possible monophosphates may be formed depending upon whether
the sugar Is phosphoxylated at the 2', 3* or 5' positions, whereas
the deoxyribonucleosides have only two free hydroxyl groups (3* aud 5')•
Moreover, the nucleoside 5* phosphates may be further phosphoiylated
at the 5' position to yield di- and tri- phosphates. Thus thymidine
may be converted to thymidine-5'-monophosphate (thymidylic acid,





BIOSYNTHESIS OF THE THYMINE COMPONENT OF DNA.
INTRODUCTION «
This topic has been the subject of excellent reviews by both
Crosbie (1?6C^ and Keichard (1959) end referenoe has been made
extensively to both of these accounts.
The thymine component of DNA may be synthesised de novo from
small molecules within the body or from preformed pyrimidine in the
form of thymidine. It is now fairly well established that none of
the pyrimidines is synthesised as such but rather as the corresponding
nucleotides. In the de novo synthesis the first compound to be
formed with a pyrimidine structure is orotic acid (uracil-6-carboxylio
acid) which is derived via carbamyl phosphate from CO,,, NH^, ATP
and aspartic acid. Uridine-5'-phosphate (uridylic acid, UMP) is
synthesised following the addition of ribose-5'-phosphate to orotic
acid and subsequent decarboxylation of the resultant compound
(orotydylio acid). The ribose component of UMP is then reduced to
deoxyribose to form deoxyurldylic acid (dUMP) and subsequent
methylation at position 5 of the pyrimidine ring results in the
formation of TLIP.
DNA thymine may also be synthesised directly from the
nucleoside thymidine by the appropriate kinases.
After the formation of TMP both pathways proceed together,
the TMP being further phosphozylated to form TTP which, under the
action of a polymerase enzyme is incorporated into DNA as TMP.
It is also known that cytidine and deoxyoytidine can act as
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precursors for the formation of DNA thymine and it is thought that
these substances do do by first undergoing conversion to
deoxycytidine-5'-phosphate (deoxycytidylic acid, dCMP) with
subsequent deamination at position six and methylation at position
five to form TMP. The exact sequence of these reactions is still
not clear and will be discussed in more detail later* For the
purpose of this thesis the cytosine derivatives may be regarded as
entering the de novo pathway for the synthesis of DNA-thymine* It
is not known whether normally synthesis from small molecules or from
preformed thymidine predominates but it is known that the methylation
of dUMP as judged by ^C-formate incorporation into DNA-thymine is
suppressed in the presence of thymidine in vitro (Prusoff et al, 1956)*
The bio8ynthetic pathways outlined in this Introductory
passage will now be considered in more detail*
THE DE NOVO SYNTHESIS OF DNA-THYMINZ.
THE BIOSYNTHESIS OF THE UKIDINB NUCLEOTIDES*
a) From small molecules*
The biosynthetic pathway for the de novo synthesis of
uridine-5'-phosphate is shown in figure 2 which is taken from the
review by Crosbie (1960^* N^ of the pyrimidine ring has been shown
to be derived from NH^ (Lagerkvist, 1953)> Cg from COg (Heinrich and
Wilson, 1950) and the remainder of the ring (N^» C^, and Cg) is
derived from aspartio acid (Lagerkvist et al, 1951| Heichard and
Lagerkvist, 1953)*
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The pathway of de novo synthesis of uridine-5'-phosphate.
Figure 2> (after Crosbie, 1960^.
The first reaction involves the interaction of COg and
ammonia in the presence of ATP and in mammalian systems of acetyl
glutamate (Hall et al, 1953) to form carbamyl phosphate (Jones et
el, 1955).
The carbamyl phosphate then reacts with aapartio acid under
the influence of aspartate carbamyl transferase to form carbamyl
aspartate (Schulman and Badger, 1954} Smith and Stetton, 1954}
Heinrich et al, 1954).
The interconversion of carbamyl aspartic and orotic acid
involves the formation of dihydroorotio acid, and in cell free extracts
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the enzymes dihydroorotase and dihydroorotic dehydrogenase which
catalyse respectively the interconversion of carbamyl aspartic and
dihydroorotic and orotic acid, (Lieberraan and Kornberg, 1953? Yates
and Pardee, 195^flL
Orotic acid is converted to UMP following condensation with
5-phosphor^bosyl-l-pyrophosphate (Kornberg et al, 1955) hy means of
ihe enzyme orotidine-5*-phosphate pyrophosphorylase (Lieberman et al,
1955) to yield orotidine-5'-phosphate which in turn i3 converted to
UMP irreversibly by orotidine-5'-phosphate decarboxylase (Kornberg et
al, 1955; Hurlbert and fteichard, 1955)•
UMP may be further phosphorylated to uridine-5*-diphosphate
(UDP) and uridine-5'-triphosphate (UTP) (Potter et al, 1954) and it
has been reported that cytoplasmic fractions from rat liver can
bring about this phosphorylation, which is dependent upon oxidative
phosphorylation reactions or the presence of ATP (Herbert et al, 1955)*
The control of pyrimidine nucleotide biosynthesis in E.ooll
by feed back inhibition has been demonstrated (Yates and Pardee, 195$)*
Cytidine and cytidine-5'-phosphate (CMP) are competitive inhibitors
with aspartic acid and carbamyl phosphate for carbamyl aspartic
formation. Uracil, uridine and UMP do not inhibit appreciably.
b) From preformed pyrimidine s.
The ability of tissue to incorporate free pyrimidines into
polynucleotides seems to vary with the tissue. The utilisation of
uracil and cytosine is negligible in rat liver unless supplied in high
extracellular concentration (Bendich et al, 1949) but uracil is
readily incorporated into the BNA of hepatomas induced by
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2-acetylaminofluorine (ilutman et al, 1954) and in the Flexner Jobling
carcinoma as well as in the normal rat intestinal mucosa (Heidelberger
et al, 1957a). Pyrimidine nucleosides and nucleotides do function as
precursors of tissue polynucleotide pyrimidines (Poll et al, 1949;
Hammarsten et al, 1949; Prusoff, 195Saj Heoht and Potter, 1956) but
the evidence available suggests that sephosphorylation of the
nucleotides occurs prior to entiy into the cell. Utilisation of
the resulting nucleoside then takes place (Liebman and Heidelberger,
1955).
THK BIOSYNTHESIS OF DSJXYRIBQNUGD&OTIDSS.
The de novo synthesis of the UNA pyrimidine nucleotides
involves the transformation of a pyrimidine ribonucleotide to the
corresponding deoxyribonucleotide. Thus -labelled cytidine and
uridine are utilised for the synthesis of both DNA and MA pyrimidines
in the rat (Haaaarsten et al, 1950). Moreover, following the
injection into rats of "^C-cytidine labelled in both the pyximidine
and ribose moieties, it has been shown that the ratio between the
specific activities of cytosine and ribose in the KNA was the same
as that between the specific activities of the pyrimidine and
deoxyribose in the DMA (Rose and Schweigert, 1955). Similar
results have subsequently been shown with CMP, UMP (Roll et al, 1956)
and uridine (Aeichard 1957).
Priedkin ana Romberg, 1957» have reported that in P.coli
extracts no kinase activity with respect to deoxyuridine monophosphate
(dUMP) is demonstrable. Recently, however, evidence has been
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obtained in favour of an enzyme which catalyses the formation of
deoxyuridine diphosphate (dUTP) from uridine diphosphate (UDP)
(Bertani et al, 1961). Further studies suggest that dUDP may be
phosphorylated to dUTP but that another enzyme which catalyses the
formation of dUMP from dUTP is also present. The absence of uracil
from DNA may thus not only be due to the absence of an enzyme
which phosphorylates dUMP to dUTP but also to the presence of an
enzyme which specifically cleaves dUTP, Figure 3 shows a possible
pathway for the synthesis of DNA-thymine as suggested by Bertani et
al (1961).
In the case of the deoxycytidine nucleotides the available
evidence suggests that they are formed in the same way as the
deoxyuridine nucleotides i.e. by conversion of the ribosyl to the
ueoxyribosyl compound at the diphosphate level (Bertani et al, I96I).
BIOSYNTHESIS OF THE METHYL GROUP OF THE THYMINE NUCLEOTIDES.
During the synthesis of thymine there occurs not only the
transformation of a ribotide to a deoxyribotide but also the
attachment of a methyl group to the pyrimidine ring i.e. the
conversion of dUMP to TMP.
Experiments with ^"C-labelled oompounds have shown that in
mammalian cells the methyl group of thymine could originate from the
beta carbon of serine (Elwyn and Sprinson, 1954)» formate (Totter et












and Sprinson, 1930), and at least in some cases, the methyl group of
methionine (Herman et &1, 1935)* It thus appears that the methyl
group of thymine can be derived from substances which can donate a
"one-carbon" unit, Crosbie (l9^8,) has shown, however, that
formate is not utilised for the synthesis of the methyl group of
thymine in E.eoli and that in these organisms methionine is not a
methyl donor,
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folic acid derivatives have been Known for some time to
function as co-factors of the "one-carbon" units. This was first
suggested by worK with microorganisms (Snell and Mitchell, 1941;
Stokes, 1944; frusoff et al, 194$) and it was demonstrated that th©
folic acid antagonist, aminopterin, greatly inhibited the utilisation
of "^-formate for the synthesis of DNA-thymine (Totter and Best, 1955;
Goldthwait and Bendioh, 1952). folic acid is first reduced to
tetrahydrofolic acid (fH. ) (Handschumaoner and Welch, I960) and the
N5, jjlO jag^hylene derivative oi' this (K^^^FH^) behaves as an "active"
one-carbon unit at the oxydation level of formaldehyde (CHgO)
(handschumaeher and Weloh, I960; Huennekena et al, 195$; nabinowitz
i960) • In oroer tiiat this folic acia derivative be provided to
cells the unstable FH, must be formea enzymatically from either
folic acid or dihydrofolic acid (FH-) or by the turnover of coenzyme
molecules. FH^ as well as being an intermediate product in the
formation of FH, which is ©nzyiaaticaliy active, is also the end
product formed from N5"10FH, when deoxyuridylie acid is converted
to thymidylie aciu (rriedkin 1959)* The conversion of folic acid
to FHg and FH^ is dependent upon the enzyme folic acid reductase
(iiuennekens et al, 195$; Osbom et al, 195$; Peters and Chreenberg,
1959; hakrzewski and fiichol, I960; Holland I96I) and it is this
enzyme upon which the folic acid antagonists, aminopterin and
amethopterin, act (handschumaeher and Welch, I96O; Holland I96I),
dither a uracil or a cytosine derivative could theoretically
act as the acceptor of the "one-carbon" unit. In the first instance
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methylation would give rise directly to a thymine derivative hut in
the case of cytosine, deamination of the formed 5-methylcytosine
derivative would have to take place and in this connection it is of
interest that a deaminase for 5-methyl deoxycytidine has been
described (Co|ien and Barner, 1957). Another point of importance
is whether the raethylation occurs before or after the conversion of
the ribonucleotide to the deoxyribonucleotide.
In an attempt, to answer these questions Reichard, (1955)
designed experiments in which a comparison of the utilisation of
5-methyluridine, deoxyuridine, uridine, thymine and thymidine for
polynucleotide pyrimidine synthesis in regenerating liver and
intestinal mucosa was made. They revealed that deoxyuridine like
thymidine is utilised almost exclusively for UNA-thymine formation.
No incorporation of deoxyuridine into DNA-cytosine was noted.
Uridine was utilised extensively for the synthesis of polynucleotide
uracil, cytosine and thymine whereas 5-methyluridine, like thymine,
showed a small but significant incorporation into DNA-thymine of
regenerating liver (but not of intestinal mucosa). The evidence
suggests that deoxyuridine is the primary "1-C" acceptor molecule in
thymine ring biosynthesis. Frie&kin and Roberts, (1956)have described
a similar aminopterin inhibited incorporation of deoxyuridine into
the DNA-thymine of chick embryo and bone marrow cells. Prusoff et
al (1958 end 1956) have shown that deoxyuridine, deoxycytidine,
uridine and cytidine increase the incozporation of ^C-formate into
the DNA-thymine of rabbit bone marrow and £hrlich ascites carcinoma
cells. The cytosine nucleosides are markedly more efficient than
the uracil derivatives. This evidence, together with the observation
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of msthyldeokycyti&ine deaminase activity in ii.ooli extracts haa
bean interpreted aa indicating the possible role of aeoxycytidine
(or a nucleotide derivative) as "l-C" acceptor molecule in
thymine ring formation#
Studies at the enayrae level on cell free extracts have also
been used to elucidate the methyLation reaction. Using Dowex-1
treated extracts of i:.coli it was shown that dUMP labelled with
^2P or was transformed to TKP in the presence of serine, FH^,
ISP and Kg1"1' (Frledkln and Konaberg, 1957). 'His saso reaction
was also found in masmalian tissues (Blakley, 1957? Phear and
Greenberg, 1957; Humphreys and Greenberg, 195s).
The rol« of vitamin B., in nucleic acid synthesis is still
obscure. Evidence has been presented for itr- participation in
dooxyribonucleoside synthesis (downing and Scfeweigert, 1956).
Others have proposed that it is concerned In "l-C* metabolism
(Binning ®t al, 1958; Bolindar and Keichard, 1959) being involved
in the me thylation re action rather than in deoxypentos®
formation.
The immediate "l-C" donor appears to be aethylene-FH^
(Blakley, 1958; Kisluik, 1957). The mechanism of the methylation
reaction is still uncertain. Two possibilities will be briefly
mentioned. The first proposes that FH^ and dUMT, are linked,
eaoh through their respective position 5, by the "active methylene"
group derived fro® formate (Greenberg and Humphreys, 1958; Friedkin, 1959).
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Cleavage of the complex to form TKP is thought to involve the
transfer of one atom of hydrogen to yield the 5-®ethyl group, with
the separation of FHg (Blafcley, 1957). FH^ is then regenerated
from FHg by the action of dihydrofolic acid reductase. The second
5-10
possibility involves the hydrolysis of the complex of dUMP and N
FH^ to yield a 5-bydroxymethyl pyrimidine derivative which is then
reduced to the 4, 5 di-hydro derivative, dehydrated and rearranged to
give TMP (Hamill et al, 1956; Cohen et al, 1956).
THE BIOSYNTHESIS OF TTP FHQM TMP.
The phosphoiylation of TMP to the corresponding triphosphate
is controlled by kinases which have been intensively studied i3
soluble extracts of h.coli. Ehrlich ascites tumour cells and
regenerating rat liver. The enzymes responsible for the
phosphorylation of thymidine and TMP to TTP are of special interest,
for although their activity is very low in extracts of normal liver,
it is pronounced in extracts of liver regenerating after partial
hepatectoay (Bollum and Potter, 1959; 'feissman et al, 1960^Mantsovanos
and CanellaldLs, 1959$). In this respect the thymidine nucleotide
kinase system differs from the kinases involved in the phosphorylation
of the monophosphates of adenine, guanine and oytidine which are of
oomparable activity in normal and regenerating liver. During the
process of liver regeneration the kinases responsible for the
phosphorylation of thymidine, TMP and TDP appear in that order, reach
maximum activity at the time of maximum DNA synthesis and then decline.
Similar findings were also found in cultures of the L strain of
16,
fibroblast innoculated into fresh medium (Neissman et al, 1960&«
Korhberg and his colleagues (Kornberg 1959 and 1960} Lehman,
1959) showed that cell free extracts made from cultures of E,coll
contained an enzyme polymerase which would bring about the synthesis
of DNA in the presence of the four predominant bases adenine, guanine,
cytoaine and thymine together with Mg++ and DNA primer. The enzyme
catalysing the reaction has been purified and experiments designed to
demonstrate the DNA synthesis from various isotopically labelled
substrates. From such experiments it can be shown that from 90-95
per cent of new DNA has its origin in the deoxyribonuoleoside
triphosphate substrates. The nucleotides incorporated into DNA
are formed by the 3* 5'~phosphodiester linkage and inorganic
pyrophosphate is liberated, A similar polymerase system has been
described in cell free extracts from Shrlich ascites carcinoma cells
(Smellie et al, 1959) regenerating rat liver (Solium and Potter, 1959)
and calf thymus (Bollum, 1960). The polymerase enzyme takes
directions from the primer whose pattern it faithfully reproduces.
Since the product of polymerase action is a conventional
double helix conforming to the 'fatson-Crick model it is not surprising
to find that specific replacement of certain bases by analogues can be
made provided that the correct hydrogen bonding relationships are
maintained in the "fraudulent" DNA so formed (Bessman et al, 1958),
Thus 5-bromuracil after conversion to the nucleoside triphosphate
can replace thymine. Such analogues will be discussed more fully '
in the next chapter.
17*
INTERRELATIONSHIP OF URACIL A!TD CYTOSINE DERIVATIVES.
A connection between cytosine and uracil derivatives is
achieved through amination and deamination reactions* The conversion
of UTP to CTP by an E,coli extract in the presence of NH^ and ATP has
been reported (Liebarman, 1955 and 1956) but uracil, uridine and
uridylic acid were not similarly utilised* In mammalian cell$
however, there is evidence to suggest that the amino group of the
cytosine derivative is derived from glutamine rather than from
ammonia (Salzman et al, 1958)*
The uracil and cytosine ring systems are also interrelated by
the cytosine and cytidine deaminase described in a variety of
mammalian and microbial cells but these systems are thought to be
catabollc with respect to the cytosine derivatives rather than
anabolic with respect to uracil and its derivatives (Simcook et al,
1957)♦
A deoxycytidylic acid deaminase is now known to exist in
several tissues* Enzymatio deamination of dCMP to dUMP in sea
urchin eggs was originally demonstrated by Scarano and Maggio (1958
and 1959) and later work with the livers of rats, chickens and rabbits
in various stages of their embryonic development suggested that the
deaminating activity is proportional to the growth rate (Scarano and
Talarioo, 1959j Maley, 1959)* for example, the enzymes are
essentially absent in normal rat liver but measurable in regenerating
liver (Maley, i960). These data suggest that the enzyme may have a
part to play in the synthesis of new LNA* In adult tissues dCMP
deaminase is less readily demonstrated particularly in the rat end
18.
rabbit but tha onsyias it peasant in tpprcoiablo quantities in tha
mucosa of tha alimentary tract of tha human especially in the
stomach and colon (Cuerritore at al, 19&0)•
At with tha uracil derivative CMP it phosphorylated by a
cytoplasmic fraction during oxidative phosphorylation to oytidine-
5**di And triphosphates (CBP tnd CTP rsspcetivaly) (Herbert et al,
1955)* CMP is formed from cytidine and inorganio phosphate in a
variety of cell systems (Brawerman and Chargaff, 1954 and 1955}
funis and Chargaff, 1956) and as no dc novo pathway of eytidine (or
urldins) aynthssis is known to exist other then via the corresponding
5*-nucleotide, the nucleotide phosphotransferase enzyme Involved may
be merely that of salvage mechanism* dCKF oen be phoaphoxylated
by ATP in the presence of the eytidine monophosphate kinase
described by Matey and the product further phosphorylatad to dCTP
by a nucleoside diphospho kinase (Maley, 1958} Lehman et al, 1959)
Caomllakia and Maateovanoe, 1958)*
BIOSYHTHESIS Of THE THYMINE ffiJCLEJTID^S AHP BNA-T?MNS
PitOM PiihFOit^b THYMINE DERIVATIVES.
Free thymine, like uracil and cytosine undergoes little or no
utilisation (keichard, 19551 Holmes et si, 1954} Plantl and Schoenheimsr,
1964} Batman, 1954} Bendich et al, 1949) for mammalian DMA synthesis.
Thymidine, on the other hand, like other pyrimidine dooxyribonueleosides,
le extensively utilised for the biosynthesis of DM-thymine in both avian
(Friedkln and oca, 1956b} Friedkin et el, 19560} and mammalian tissues (Malty,
1956} Cresnberg end Humphreys* 1956} Friedkin £ Wood, 1956b}Frisdkin §t al 1956c)*
19.
The pathway of thymidine utilisation has been elucidated by the
observation of kinase activities in cell free preparations of
mammalian (Canellakis and Mantsovanoa, 1938; Bollum, 1938; Bollua
and Potter, 1938; Weissman et al, i960) and bacterial origin (Lehman
et al, 1938)* Thymidine is phosphoiylated by thymidine kinase to




AGENTS WHICH INFLUENCE THa BIOSYNTHESIS OF
THE THYMINE COMPONENT OF DNA.
INTRODUCTION!
The important phenomenon of "thymineless death" of baoteria
(Cohen and Barner, 1956) has, of recent years, stimulated interest
in antimetabolites which might bring about such a state* Many of
the compounds which have been prepared bear a close resemblance to
normal metabolites except for certain minor structural alterations*
For example, uracil may be modified by replacement of the hydrogen
atom, in position five of the pyrimidine ring by a fluorine atom
(5-fluorouracil) or the hydroxyl group in position 4 of the pterldine
ring of pteroylglutamic acid may be replaced by an amino group
(amin©pterin). Alternatively, the ring structure itself may be
altered as in azauracil and asathymine where the carbon atom in
position 6 of the pyrimidine ring is replaced by a nitrogen atom*
Such oompounds are sufficiently similar to the normal metabolites as
to participate in or inhibit certain speoifio metabolic reactions*
Although much can be learned from in vitro studies with these
drugs about their site of action, in vivo studies are of very great
importance when considering their effectiveness as chemotherapeutic
agents* Some compounds, for example, act as antimetabolites only
after they have undergone alteration* In the oase of the halogenated
pyrimidines^conversion of the analogue to the mononucleotide, or
higher metabolic forms probably takes plaoe and while this particular
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reaction occurs intracellularly and can be demonstrated in in vitro
experiments, certain other reactions such as deamination of cytosine
derivatives may have to be carried out in specialised organs such as
the liver and require in vivo studies to evaluate fully the
therapeutic efficacy of the drug. Moreover, some compounds, although
active, may not be transported to certain areas of the body (e.g. the
brain) and their value as chemotherapeutic agents is therefore
limited* Other compounds may be rapidly catabolised and excreted
in the urine having been present in the body in adequate concentration
for insufficient length of time to produce any significant metabolio
effect. Finally, different tissues may utilise the analogue to
varying degrees giving rise to a selectivity of action which in vitro
studies would not reveal.
It should be stated, however, that while experiments with
whole animals will give considerable information it is to be noted
that not all species respond in the same way to any particular
compound* In some instances man may respond in a way that is unique
so that not until it has been administered to man himself can the
drug be fully evaluated* For example, azauridine is very toxic to
the bone marrow of the dog but it is thought to have no effect on the
haemopoietic tissues in man*
Compounds which inhibit the synthesis of DKA-thymine fall into
two main groups* Those which interfere with the formation of TMP and
those which interfere with its utilisation i*e* its further
phosphorylation and incorporation into INA* Brief mention will be
made of the various classes of compounds which interfere with the
^2 *
synthesis of LFA-thymine but only the halogenated pyrimidine s will be
discussed in detail since it is with these drugs that much of the
experimental work to be described later was undertaken.
COLi-Lbl'iAS .HIGH INHIBIT THa FO&.IATION Of TLJ.
FOLIC ACID A:T..^U:I3I'3»
Aminopterin and ^jmethopterin.
Many derivatives of folic acid have been prepared (Seeger et
al, 1947) but of these Aminopterin and Amethopterin are by far the
most important. Aminopterin is derived from folic acid by the
substitution of an amino group for a hydroxy!, group in the 4 position
and amethopterin is the N^^-methyl derivative of aminopterin. These
compounds serve as antimetabolites by virtue of their action upon the
enzyme folic acid reductase (Peters and Greenberg, 1959J Zakrzewski
and Nichol, I960; Qsbora et al, 1958j Huennekens et al, 1958{ Nichol
and 7.relch, 1950) which is involved in one carbon transfer reactions
not only for the synthesis of TMP but also for the biosynthesis of
the first purine-containing compound, inosinic acid, which subsequently
is converted into adenine and guanine containing components of nucleic
acids and many coenzymes. The affinity of folic acid reductase for
the 4-amino derivatives of folic acid is so great as compared with its
affinity for folic acid itself or dihydrofolio acid that the effects of
the drugs are long lasting and impossible to overcome by the
administration of folic acid. However, early signs of toxicity may
be prevented by giving folinic acid whioh is a relatively stable
derivative of FH^ and wliich supplies the product of the blocked reaction
(FH^) but does not actually release the enzyme from its inhibition
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(Brocjuist et al, 1950; Burchenal and Babcock, 1951; Sauberlich and
Baumann, 1943; Schoenbach et al, 1950).
These compounds are very effective in inducing excellent
remissions in many cases of childhood leukaemia (Farber et al, 1943)
and certain other types of malignancy, particularly chorion epithelioma
(Hertz et al, 1953), Recent evidence suggests that their
effectiveness may be related to the relatively short supply of
folic acid reductase in the susceptible cells (Bertino et al, I960; 8&d
196l?.)and that the development of resistance to the drug is related to
selective reproduction of cells rich in this enzyme (Bertino et al,
Fischer 1959 end I9SI)
Biamino-pyrimidines and Diaminodihydrotriazlnes*
Several compounds with the structure of a diatainopyrimidine
or a diaminodihydrotriazine have been prepared. These compounds
are thought to act by interfering with the formation of a coenzyme
closely related to FH^ and therefore with the synthesis of nucleic
acids (Swaffield et al, 1959). Direct studies of the effects of
these agents on folic acid reductase have, however, not been made.
Two antimetabolite drugs, chlorguanide and pyrimethamine are of
interest in this group of compounds. The latter is a diaminopyrimidine
and the former is thought to be converted to a diaminodihydrotriazine
within the body. The evidence suggests that both compounds act by
interfering with the formation of FH^ or closely related compounds by
certain plasmodia (Hitchings, 1952; Modest et al, 1952; Foley, 1953;
Swaffield et al, 1959)•
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UIGTHA?^.
Ethyl carbamate (urethane) has the capacity to affect
cellular reproduction and nuoleio acid metabolism but its mode of
action is uncertain# It acts as an inhibitor of various transplant-
i able neoplasms (Zlion et al, l958$;Haddow and Sexton, 1946) and is
used to a limited extent in the treatment of multiple myeloma
(Peterson et al, 1946; Berman and Axelrod, 1948? Loge and Rundles,
1949)• Urethane has also been shown to induce neoplasms in certain
strains of mice and rats and the neogenic action was reduced by the
presence of thymine but less so by thymidine (Rogers 1951* 1955*
1957 (a) and 1957 Since thymine is poorly utilised for DNA-
thymine synthesis and is rapidly and extensively degraded (heichard,
1955; Prusoff et al, 1954; Fink et al, 1956) the possibility that it
may be used for the formation of substances other than UNA-thymine or
may exert indirect effects must be borne in mind# It has been
suggested that urethane influences the formation of the pyrimidine
nucleus from carbamyl phosphate and aspartic acid, and the methylation
and the amination of the uracil moiety but much more work is required
to explain satisfactorily the effects of this compound#
PYBiri3DIN5 /JT.ALOSUES#
5-Amino-# 5-me rcapto-pyrimiflines >
Aminouracil is thought to exert its antimicrobial activity
by acting both as an antifolic and as an antagonist to thymine
(Eitchings et al, 1945 and 1950)# Axainodeoxyuridine inhibits the
growth of B»coli 4-12 and the inhibition is overcome best by
thymidine (Belts and Visser, 1957) suggesting that the drug inhibited
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the formation of thymine nucleotides*
5-mereaptouracil effectively inhibits the growth of
L.leichaannii and it3 action is reversed by thymine, or more effective-
tly by thymidine (Bardos et al, 1955) in. a competitive manner. When
combined with fluorouracil this compound was also effective in
producing significant inhibition of the growth of the animal tumours
sarcoma-180 and aasno carcinoma-755 which has been interpreted as
being due to multiple blockage of de novo synthesis of thymine
derivatives and utilisation of preformed thymine (Bardos et al, 1959)
A zap.yrimidine s«
The azapyrinidines are formed by replacement of one of the
ring carbons and its associated hydrogen with a nitrogen atom,
Azauracil and its derivatives end azathymine are of particular
interest with regard to D!IA-thymine synthesis.
Azauracil and its metabolic derivative 6-azauridine have
both been found to possess antimicrobial activity (Handschumacher
and Welch, 1956), but azauridine is a more effective inhibitor of
tumour growth (Jaffe et al, 1957} Sorm and Kellova, 1958) presumably
due to the fact that mammalian cells convert azauracil to the
corresponding ribosides relatively poorly (Jaffe et al, 1957).
Azauridine is further converted to the nucleotide derivative
(Habermann and Sorm, 1958} Pasternak and Handschumacher, 1958}
Handschumacher and Pasternak, 1958} Pasternak and Handschumacher, 1959)
which inhibits the enzyme orotic acid decarboxylase. As a result,
orotic acid is found in the urine (Habermann and Sorm, 1958) and the
de novo synthesis of KNA and DHA pyrlraidines (including thymine) is
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inhibited (Pasternak and Handschumacher, 1959)*
Azathymine is an effective inhibitor of the growth of many
organisms and the inhibition can be overcome in a competitive manner
by thymine or thymidine (Prusoff et al, 1954; Elion et al, 1954)*
The analogue exerts its effect on organisms utilising exogenous
thymine or thymidine and on those synthesizing it &e novo.
/zathymidine was an even more potent inhibitor than the free
pyrimidine ( Prusoff and "Telch, 1956) • Azathymidine but not
azathymine will inhibit the incorporation of formate into the DNA
thymine of rabbit bone marrow cells and Ehrlich ascites cells in vitro
(Telch et al, 1955; Prusoff et al, 1956; Prusoff 1959) whereas
incorporation of thymidine was relatively insensitive to azathymidine.
These results are not strictly comparable, however, since in the
former case the azathymidine was competing with what are probably
only very small amounts of thymine nucleotides.
Uracil Hethylsulphone.
This compound is a potent inhibitor of certain microorganisms
(Holmes and Welch, 1956) and a number of tumours (Jaffa and Cooper,
1958). In Ehrlich ascites cells the uptake of formate and orotic
acid into ENA thymine is- inhibited though the analogue has no effect
on the utilisation of preformed thymidine (Prusoff, 1958).
Eluorinate d Pyrimidine s.
Several compounds have now been synthesised in which the
hydrogen atom at position 5 of the pyrimidine ting has been replaced
by a halogen atom. In particular, the halogenated uracil compounds
and thymine have similar physical and chemioal properties so that a
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considerable amount of work has been undertaken to elucidate the
mechanism whereby these compounds influence the synthesis of DFA-
thymine. Fluorine has a van der Waal's radius of 1.35 A as
compared with that of hydrogen of 1.20 A, whereas that of iodine is
2.15 A. bromine 1.95 A and chlorine I.85. It can thus be appreciated
why fluorine which bears close similarities in physical and some
chemical properties to hydrogen substitutes for the latter in
certain biologically active compounds. Iodine and bromine, on the
other hand, substitute at position 5 of the pyrimidine ring for a
methyl group which has a van der Waal's radius of 2.0 A. In
consequence fluorinated uracils serve as uracil analogues whereas
iodinated or brominated uracils serve as thymine analogues. The
chloro derivative apparently behaves as both a uracil and a thymine
analogue since it is incorporated into both RNA and DNA of micro¬
organisms. 5-fluoro uracil was the first of the fluorinated
pyrimidines to be synthesised (Duschinsky et si, 1957s)but fluoro
deoxyuridine, fluoro-orotic acid (Chaudhuri et al, 1958), fluoro-
cytosine (Heidelberger et al, 1957) fluoro-cytidine (Duschinsky et
el, 1957) and fluoro-deoxycytidine (Duschinsky et al, 1957)) Cohen
et al, 1958) have all been synthesised and tested subsequently,
(a) 5-Fluorouracil (5-FTJ).
This compound inhibits the synthesis of the uracil and cytosine
components of ENA and, following conversion to 5-fluoro-deoxyuridylio
acid, that of DNA thymine as well.
It has inhibitory activity for a wide spectrum of micro¬
organisms (Heidelberger et al, 1957j Scheiner et al, 1957) which
can be reversed by thymidine in a non-competitive manner and to a
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lesser decree by uracil or cytosine, Inhibition of ft variety of
mouse tumours has also been observed (Heidelbergar «t el, 1957}&ad
19S»i). la ~hrllch ascites tumour cells in vivo format#
inccip oiatio.i into 11JA~thymine was inhibited and orotic acid
incorporation into LlIA-thymine arid iJiA-uracil was also inhibited
(ileidelLsrger at al, 1957} lanneberg et al, 1958). At the same
time tiiyiiiicine incorporation into LI.'A was increased suggesting that
tire mode of action of fluorouracil is> following its conversion to
5-fluorodeoxyuridylic acid, the inhibition of the conversion of
uracil derivatives to thymine nucleotides with consequent
utilisation of exogenous thymidine* Inhibition of the thymidilate
synthetase reaction has also been demonstrated in a coll free system
(lleidelberger ana hartmann, 1961} I'arkas et al, 195o)* That
fluorouiacil also effects the synthesis of HJA-pyrimidines was
evident from the faot that in the same dosage It produced up to
68 per cent inhibition of the incorporation of uracil or orotic aoid
into the uracil or cytosine of BNA (lleidelberger et al, 1957b;
lannebsrg et al, 1958)*
In vitro studies have shown that in general fluorouracil
undergoes all the anabolic reactions of uracil (Harbers et al, 1959}
Chaudhuri et al, 1958; Bosch et al, 1958), with the exception of
methylation at position 5 of tire derivative corresponding to dUMP,
this site having been blocked by the fluorine atom* Incorporation
of fluorouracil into the hHA of many mouse and human tissues also
occurs (Chaudhuri et al, 1958)* ./hether it replaces any specifie
ANA base cannot definitely be stated but no significant incorporation
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of the analogue in the forn of fluorocytosine has so far been noted
in the KNA or t' ^ of mammalian or bacterial cells* Since fluorouracil
inhibits the incorporation of both orotic acid and uracil into RHA-
pyrimidines it has bean postulated that it inhibits an enzymio site
of action at the ribonucleotide level beyond ULIP but proof of this is
still awaited ('.elnick et al, 1958).
As a result of tnis disordered metabolism interesting changes
may be observed in growing cells by the use of cytocheraical techniques
(Lindner, 1958 and 1959)* In Lhrlich ascites cells treated with
fluorouracil there wa3 a reduction in the mitotic index with enlarge¬
ment of the cells which contained an increase in the amount of protein
and RITA within the cells. The LNA content was reduced by 50 pe*" cent.
Feulgen staining of interphase cells demonstrated coarse clump3 and
strands of LNA around the nucleus indicating early death.
Of considerable interest with regard to this compound are the
reports indicating marked differences in mammalian tissues in the
capacity to utilise preformed uracil (Rutman et al, 1954; Heidelberger
et al, 1957?-; Legerkvist and Reichard, 1957; Reichard and Skold, 1958).
For example, the analogue wa3 found to inhibit the incorporation of
II
C-formate into the thymine of LNA in Rhrlich ascites cells
preferentially as compared with spleen, liver or intestines. Moreover,
preferential concentration of the fluorouracil derivatives in a
number of experimental tumours and in human neoplastic tissues
following its administration in vivo has been noted (Chaudhuri et al,
1958),
<*) 5-Fluorouridine and 5-Fluorodeoxyuridine.
These compounds have many biological properties in common with
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fluorouracil (Harbers et al, 1939* Bosch et al, 1958).
Fluorodeoxyuridine, however, has an even greater affinity for tumour
(sarcoma-180) than fluorouracil while fluorouridine has less (Harbers
et al, 1959). Fluorodeoxyuridine has a greater inhibitory effect
on tumours in vivo (Heidelberger et al, 1952$ and it causes a
"thymineles3" death of F.coli but its length of action is limited owing
to its degradation to fluorouracil by deoxyribonucleosides (Cohen et
al, 1958).
Since the mechanism of action of fluorouracil and its
deoxyriboside, involves an inhibition of the thymidylic acid
synthetase system it would be logical to expect that thymidine might
antagonise their action as a result of the formation of TUP by the
action of thymidine kinase. This is the case with fluorodeoxy¬
uridine if thymidine is administered intravenously simultaneously
with the analogue (Killer et al, 19&1) but in certain circumstances,
thymidine actually increases the toxicity of the drug (Burchenal et
al, 1959a&n& i960). Thi3 may be attributed to the rapid catabolism
of both compounds. Thus thymine is released from thymidine and
fluorouracil from fluorodeoxyuridine. Thymine then competes with
fluorouracil for further catabolio enzymes and thus permits increased
utilisation of the analogue with a consequent increase in toxicity,
(c) 5-Fluoroorotic jcid.
This compound behaves in a manner similar to fluorouracil
particularly with reference to synthesis of DNA pyrimidines
(Heidelberger et al, 1957) 'but it is not utilised preferentially
by tumours (Chaudhuri et al, 1958). In addition, fluoroototic acid
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Inhibits ths synthesis of orotidylic eoid from orotio sold end
l-pyrophoaphorylribose-5-phosphate (Stone and Potter, 1957).
(d) 5-Fluorooytosine. S-Pluorocvtldlra and 5-FluorodsoxvcvtltUne.
Fluorocytosine has little biological activity but the
corresponding riboside and daoxyriboaide do reduce the rate of
growth of experimental tumours (Burchenal at al, 1958 and 1959b;
lidinoff et al, 1959c). In vitro studies with Ihrlieh ascites cells
indicate that fluorocytidino appears to act asinly by inhibition of
the incorporation of uracil and cytldine into DM thymine (Kartere et
al, 1959)» which suggests that the compound acta after it* deamination
to for* the corresponding uracil derivative*, the deamination occurring
either before or following Its conversion to the dsoxyrlbotlde.
co?<poohds which imiibir ths utilis.atiot of tmp.
Of tho drugs which fall Into this category only the halogonatod
pyrimidinea will be considered, when the pyrinidine ring is halogenated
in position 5 by ohlorins, bromine or iodine, the compound may be regarded
primarily as a thymine analogue since the larger van dor Waal's radius of
theso atoms mors closely resembles that of a methyl group than a
hydrogen, A striking property of these compounds is their capacity
to replace thymine residues in DMA, Bromuraoil (weygaad at si, 1951}
hitman and Pardee, 1958} Dunn and Smith, 195% Zaaenhoff and Grlboff,
1954)* iodouracil (Dunn and Smith, 195% Zamanhoff and Griboff, 1954)#
bromodeoxyuridins (Kit et al, 1958} Sidinoff et al, 1959b),
iododeoxyuridln® (Prusoff 1959b) and ohlorouracil (Dunn 1957) have all
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been 3hown to be extensively incoxporated into DhA of bacterial or
mammalian systems in some instances replacing 50-100 P®*" cent of the
thymine component (.acker et al, 1954; Frusoff et al, 1953)*
HALOGEN; T_, I) Ik., 01..d,
Chloro-, bi o.t.o-, and iodo- uracil inhibit tne growth of
microorganisms ^ditchings et al, 1945; Lunn and Lmith, 1957)* Under
certain conditions, however, they may actually stimulate growth
(ditchings et al, 1945;and. 1948; Frusoff, 1954) and bromodeoxyuridine
can substitue for tliyuiaine for short periods in the reproduction
of lie la cells in culture under conditions in which thymidine is
normally required (ilakala, 1958). In so far as they have been
investigated, the halogenated uracils are much less active in
mammalian systems than the corresponding nucleoside derivatives and
consequently axe poor- inhibitors of tumour growth (Kit et al, 1958;
Eiainoff et al, 1957 and 1959b Prusoff et al, 1953)*
HAL^GENAl'Eh WCIL.
Chlor-, bromo- and iodo- uridine have all been synthesised
but they have not been found to possess striking biological activity
(Kit et al, 1958; -uiuinoff et al, 1957 and 1959^). The utilisation
of iodouridine by normal tissues, regenerating rat liver and
experimental tumours In vivo has been investigated (Frusoff, 1953) hut
significant accumulation of the compound in these tissues did not
occur. There was, however, a relatively high concentration of iodine
in the thyroid gland indicating extensive metabolic degradation of
the analogue,
HALOGEN/TED DnChYhllASIIAS OF thi/CIL.
Bromodeoxyuridine and Chlordeoxyuridine,
Both these compounds can replace 30~&0 per cent of the
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ENA-thymine of human cells grown in culture without loss of viability
(Ejordjevic and Ssybulski, 1260; Saybalslci and tjordjevic, 1959).
This incorporation can ho facilitated by inhibition of the thymidylio
synthetase reaction bj the addition of fluorodeoxyuri&ine to the
medium. Under thc^e conuitions the fui'ther addition of
bromodeoxyuridine stimulates tne reproduction of the cells ana gives
rise to furthc-r incorporation of the analogue. ,^hen both strands
of UNA have a sufficiently large proportion of the methyl groups of
their thymidylic acid content replaced with bromine the threshold of
radiation sensitivity is thought to be reduced (Ejordjevic and
Szybalski, i960). (tee below).
Bromodeoxyuri&ine does not possess strild-ng antitumour
activity when used without combination with radiation (Jaffe and
Prusoff) but a modeinte inhibition of tumour cell reproductive
capacity of mouse leukaemia cells has been reported (Berry and
Andrews, I96I). It appears to have little or no toxicity for mice
or humans (Holmes et al, 1954).
Iododeoxyuridir? (iUdli).
Thymidine is an efficient precursor of EKA-thymine (heichard
and Estborn, 1951; Plentl and Schoenheimer, 1944) but the other
methylated uracil derivatives such as thymine (Plentl and Schoenheimer,
1944; Brown et al, 1952; Holmes et al, 1954) and 5-niethy 1orotic-acid
(Holmes and Prusoff, 1954) and 5-niethyluridine (l'riedkin and Aoberts,
1954) are not. It i3 therefore not surprising that the corresponding
iodinated derivatives (iodouracil, iodoorotic acid and iodouridine)
did not inhibit the biosynthesis of ENA-thymine or that they were not
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incorporated into MA. (rrusoff, 1954 and I96O91), However, since
thymidine is an efxicient precursor of vliA-'thymine the corresponding
analogue (iododeoxyuridine, (IUcLij ight be expected to fulfil both
these functions,
Prusoli first synthesised lUdtt in 1959®* Ahen deoxyuridine,
iodine, chloroform and nitric acid were refluxed gently together
white needle crystals of I'udu were formed. As expected it was found
that this compound inhibited the utilisation of radioactive thymidine
for the biosynthesis of biuj-thymine in dhrlich ascites carcinoma
cells in vitro (rrusoff, I96O9.). koreover, IUdK also inhibited
the incorporation of ^"C-orotate and "^C-formate into DNA-thymine
but not of "^'C-orotate into the oytosine of hi'A or into the cytosine
and uracil of (rrusoff, i960)• In contrast to fluorodeoxyuridine
(Cohen et al, 125o> barbers et al, 1959)# lUdh appeared to inhibit
the utilisation of !LJr> rather than its formation (Prusoff, 1960?.;
hit et al, 1953), moreover, by growing mammalian cells in the
presence of radioactive lUdri and then examining their 11!A it can be
shown that a large proportion of LAA-thymine may be replaced by the
iodinated analogue (Prusoff, 1953b and i960]?; Alathias and fischer, 1959k)'
For example, after a single reproduction of mouse lymphoma L5178Y
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cells in culture, in the presence of 1-Udh approximately one third
of the Tj.J? component of LI IA was replaced by iododeoxyuridylio acid
(kathias et al, 1959b). Similar results have been obtained in vivo
when IUdR has been administered to mice bearing Ehrlich ascites
tumour cells (Prusoff, 1959,c»). Under these circumstances, however,
thymidine was utilised preferentially to a fortyfold greater extent
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than IUdd,
(a) /.ntitumour .'ctivita in xodeuts.
IUdu w£.s found to inhibit the rate of giowth of several
experimental tumours by 50 per cent or more as compared to the
growth rate in untreated control animals (Jaffe and Prusoff, lj6o)»
The drug was administered by intraperitoneal injection in a dose of
100 to 150 nig./kg, body weight and in this dosage did not produce
significant host toxicity. In a similar dosage it was, however,
found to be ineffective on the growth of '.alker carcinosarcoma 256
in young rats. Jnly additive effects on the growth of lymphoma 1210
were seen when lUdu was administered to mice in combination with
azathymine, asauridine, fluorodeoxyuridine or ainethopterin. The
combination of IUah and 6-mercaptopurine for reasons not understood
produced less than additive effects,
(b) In vivo metabolism of lbAn..
131 3
The metabolism of lUcLt labelled with 1 or VH appears to
involve the cleavage of the deoxyribose moiety with the formation of
iodouracil which is subsequently dehalogenated (prusoff et al, 1960p)
to form uracil ana inorganic iodide. Direct deiodination of lUdH
has not been observed. The breakdown of IUdR to uracil and iodide
occurs very rapidly, some of the iodine being utilised to iodinate
the proteins of the tissue. 74 per cent of the radioactivity of an
intraperitoneal dose of "^^l-U&R in mice appealed in the urine within
4 hours and 91 per cent with 24 hours (Prusoff et al, 1960c ). About
83 per cent of the radioactivity was present as free iodide, the




In Iwiss mice the LE50 of XUcLR was 2.5 g»/kg. when administered
in a single dose. The LD50 upon repeated daily administration of
the drug was 312 mg,/kg. The toxicity could be completely prevented
by prior adninistration of thymidine (Prusoff et al, 1960p)
Coses of 100 mg./kg, to dogs for 10-20 days produced anorexia,
leucopenia, thrombocytopaenia and occult blood in the stools. There
was inhibition of cellular proliferation in the blood forming tissues
and in the intestinal epithelium (Telch et al, I960).
Iododeoxycytifline (iCdR).
The halogenated derivatives of deoxycytidine have been
investigated in the hope that they might have greater metabolic
stability, which in turn might result in their more extensive
incorporation into the acid soluble nucleotide pool3 as well as into
CriA. There is evidence to suggest that the amino group in lieu of
oxygen in position 6 of the pyrimidine ring results in greater
metabolic stability. The cytosine containing nucleosides, unlike
those of thymine and uracil, do not participate in certain enzyme-
catalysed reactions which lead to displacement of their sugar
component (Verdier and Potter, i960). The enzyme deoxycytidylate
deaminase has been found to be present in rapidly growing mammalian
tissues such as neoplasms, embryonic tissue, regenerating liver,
thymus and bone marrow but has been reported to be absent in most
normal tissues. Recently, however, high concentrations of the
enzyme have been found in the kidney (Creasy, 1962),
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lododooxycytidin© was first aynthesised in 1961 (Change sad
eleh, 1961b) and so far has bean investigated only slightly* As
predloted, however, it acta in the same way as lUcdi but is is
catabolised surprisingly quickly (eraser et al, 1962). following
the Injection of mice with %-iododeoxyoytidine, chromatography of
the urine showed the drug to be rapidly and extensively nwtaboliaed.
It is, however, less toxic to mice than lUdH and this together with
its increased solubility in water and resistance to thermal
decomposition in solution offer the possibility of significant
advances over XUdii in the treatment of neoplastic disease*
Bromodeoxycytidlns *
BroLiodeoxycytiaine was also synthesis®! (Chang and Welch,
1961a) because of the possibility of its greater metabolic stability*
It has been shown to be resistant to nucleosidases (Cramer et al,
1961) in vitro ana moreover in mice and rats in vivo the bromide
appeal's to be cleaved from it less readily than from bromodeoxyuridine
(Kriss et al, 1961)* Tritinted broiaodeoxycytidine has been shown to
be incorporated into MA as 5-brorao-2*-ueoxyuridylic acid replacing
an equivalent amount of TfcSP* Whether phosphorylation precedes or
follows deamination has not been determined but the metabolic
conversion of bromodaoxycytidine to the deaainated derivatives has
been observed both in a ceil free system and in intaot neoplastic
murine mast cells (P875Y). *hen administered in rat#, 82Br-
broEodeoxycyticdne is distributed differently through the body from
eht-bromodeoxyuridine. This may be due to the concentration of
deoxycytidylate activity in certain tissues such as the bone marrow*
38.
Unfortunately, rapid debromination takes plaoe in man following
intravenous administration of bromodeoxycytidine (Welch, 1961) and





CLI 'IC .L smi.r" nv,i THS IKLQo&iatsd PYKIMlDmS.
Extensive clinical trials have bean carried out with
fluorouracil and initial studies have been made with fluoiodeoxy-
uiidino, iodoasoxyuridine ana brasodeo^yuridine •
5-Pluorouracil and 5-iluorodeoxyuridine.
Over 3,000 cases of advanced neoplastic disease have been
treated with fluorouracil and fluorodeoxyuridine in various centres
mainly in the United States of America and trials are now beginning
in the United Kingdom. Both drugs have been found to be of value
in various forms of advanced carcinoma but particularly in carcinoma
of the breast and bowel (Ansfield and Curreri, 1959 and I960} Young
et al, I960) Hurley and Hall, I960; Vaitkevicius et al, 196la; eias
and Jackson, 1961; field, i960) ana encouraging results have been
obtained in the treatment of carcinoma of the oropharynx, stomach,
uterine cervix, ovary, urinary bladder and hepatoma (loung et al,
I960; Vaitkevicius et ai, (196la and b)j Weiss and Jackson, 1961;
field, I960; Calabresi et al, I960; Cornell et al, I960; Staley et
al, 1961; Daren and Wilson, I960; Wilson, i960). The compounds are
not very effective against eithor acute or chronic leukaemia (Curreri
et al, 1958; Wolnan and Gens, 1959; Kartraan et al, i960) or against
malignant melanoma, hypernephroma, carcinoma of lung, pancreas,
prostate or oesophagus (Staley et al, 1961; Curreri et al, 1958;
Hurley and Hell, I960; Corle, I96O; Ferguson ana Humphrey, i960).
Preliminary results indicate (Curreri and Ansfield, 1962) that
fluorodaoxyuriain© in good risk patients has a superior therapeutic
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index to fluorouracil, and that it is superior as a palliative agent
in the treatment of cancer of the breast, colon and rectum. It is,
however, equally toxic and associated with a very narrow therapeutic
index in poor risk patients. When fluorodeoxyuridine is
administered in a dose of 3®g./Kg./day by continuous I.V. infusion
it is said to produce equal toxicity to that of 30mg./Kg./day given
(Sullivan et al, I960) by rapid daily injections over a similar period.
Further work has demonstrated that while this may be so the later
dosage regimen produces a much greater clinical response suggesting
that the method of administration greatly influences the site of drug
aotion (Ansfield et al, 1962).
Although regression of the tumour occurs in certain
circumstances there is no case on record of complete disappearance
and there is no conclusive evidence of actual prolongation of life
(Hurley and Hall, I960; Corle, I960; Ellison, 1961).
The degree of improvement following the administration of a
drug to a patient suffering from advanced neoplastic disease is always
difficult to assess and in an attempt to put this on a more scientific
basis Ansfield and Curreri (1959) have laid down certain criteria of
response to either fluorouracil or fluorodeoxyuridine which are
probably applicable to other drugs of this category. They are as
follows!- (1) a measurable reduction in tumour size, (2) general
symptomatic improvement, (3) improved physical performance, (4) gain
or maintenance of body weight and (5) persistence of all these features
for at least 2 months. Other criteria have also been recommended
(Ansfield and Curreri, 1959} Curreri et al, 1956) by the same workers
for the selection of patients for treatment and they are as follows:-
(1) good nutritional state, (2) no major surgery for at least 30 days
prior to therapy, (3) adequate bone marrow function i.e. absence of
evidence of marrow infiltration by tumour tissue and no previous
therapy with X-rays or ankylating agents and (4) good renal function.
Patients who fulfil these criteria are treated with 15 mg. of
fluorouracil per Kg. by rapid intravenous infusion daily for 5
successive days. If there are no toxio manifestations within the
next 48 hours, the drug is given in half that dose on alternate days
to a maximum of 4 doses. If the patient does not fulfil these
criteria he is given a modified course of the drug which consists of
15 mg./Kg, for 3 successive days followed by a dose of 75 mg./Kg. on
the fifth day (Ansfield and Curreri, 1959} Curreri et al, 1958).
Fluorodeoxyuridine is administered in exactly the same way but in
twice the dose (in mgm.) used for fluorouracil.
The toxic effects of both compounds are seen mainly in the
bone marrow and gastrointestinal tract (Young et al, 1960} Ansfield
and Curreri, 1960} Vaitkevicius et al, 1961} Calabresi et al, 1960}
Curreri et al, 1958} Moore and Koike, 1960} Perguson and Humphrey,
i960). The patient may first complain of anorexia and nausea and
these symptoms are shortly followed by stomatitis and diarrhoea. The
stomatitis may proceed to ulceration and necrosis (Calabresi et al,
i960) and similar lesions have been seen in the colonic mucosa at
post mortem (Cold et al, I960). Bone marrow changes take the form
of an increase in the myeloid erythroid ratio (Vaitkevicius et al,
I96H) with megaloblastic change in the red cell series in some
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instances (Brennan et al, i960). These ohanges progress to
hypoplasia or aplasia of the bone marrow with a pancytopaenia in
the peripheral blood. Leucopaenia is usually most marked between
the 9th and 11th day3 after the commencement of therapy but may occur
anywhere between the 5"th and 21st day (Vaitkevicius et al, I96I;
Curreri et al, 1958)* It is likely to be particularly severe in
patients who have previously been treated with alkylating agents
and radiotherapy to the spine or pelvis (Young et al, I960;
Vaitkevicius et al, 196l95Calabresi et al, I960; Curreri et al, 1958)*
Another side effect of these drugs is hair loss, which is
usually slight but may progress to total alopaecia (Vaitkevioius et
al, 196]q_,Curreri et al, 1958). Other epidermal structures such as
skin and nails may also be affected giving rise to dermatitis,
pigmentation of the skin and ridged nails (Vaitkevicius et al, 1961^
Curreri et al, 1958). Neurological changes have been reported
(Staley et al, 1961) and myelopathy following intrathecal administration
was seen in one case (Koenig, 1959)*
Bromodeoxvuridine♦
This compound has little or no effeot on malignant or normal
tissue when administered to man but preliminary studies have
suggested that its incorporation into the DNA of malignant cells may
lower their threshold of radiation sensitivity (Brennan et al, i960).
Iododeoxvuridine. (lUdS),
Preliminary clinical studies with IUdE have been reported
(*,Velch and Prusoff, 1961; Calabresi et al, I96I). Patients with
advanced neoplastic disease not amenable to surgery were treated
with the compound and significant tumour inhibition was noted in some
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patients with malignant melanoma, fibrosarcoma, epithelioma of the
tongue and mucoepi&eraoid carcinoma of the parotid gland. Only modest
tumour inhibition was obtained and this was accompanied by significant
toxicity.
The compound was administered intravenously. IU&R is a weeklj
acidic compound which is poorly soluble In alkaline solution and which
is partially decomposed by antoclaving. It was, therefore^ prepared
for intravenous administration by sterile filtration of a solution of
3 per cent glucose pH 3.6 containing 6 rag. of XUdK/ol, Daily doses
of 17 to 121psg./kg. were administered over a period of 1 to 3 hours*
A total dose of 60 to 720 mg. was given over a period of 2 to 7 days.
The same workers ore at present experimenting with different dosage
regimens infused over longer periods of time, thus making the drug
available for cellular metabolism during an increased number of
reproductive cycles.
Following the infusion of ^"1-UdR in doses of 80mg./ke* and
100 ag./kg. respectively in two patients, the level of radioactivity
in the blood progressively fell reaching 50$ of the five minute level
in 7 to 10 hours. Twenty four hours after the cessation of the
infusion 88 per cent of the radioactivity was removed in the urine.
Urine collected during the Infusion contained about 50 per oent of
its radioactivity as iodide and chromatography of the urine demonstrated
that the IUdR was undergoing rapid destruction in the human subject
with the formation of both iodouracil and iodide.
No immediate toxic effects have been noted in man except for
mild iodiam which consisted of oedema of the mucous membranes, ptyalism
and atneform dermatitis. Delayed toxic effects are almost identical
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to those seen with fluorouracil and fluorodeoxyuridine but the
alopaecia tends to be more severe# The three effects most easily
observed are leucopaenia, stomatitis and alopaecia and in patients
receiving over 600mg./kg« body weight all three were invariably
present. Anorexia, diarrhoea, nausea and vomiting occasionally
occur but are less common than with fluorouracil. Thrombocytopaenia
and nail changes are occasionally seen. Some of the undesirable side
effects can be prevented by the use of thymidine. Calabresi (1961)
recently treated 4 patients with an infusion of thymidine (4 mg./kg.)
into one external carotid artery for about 4 hours beginning about
15 minutes before a 2 hour intravenous infusion of IUdR in a dose of
120 mg./kg. This was carried out on 5 successive days. The drug
produced a leucopaenia but stomatitis was prevented completely and
hair loss was prevented on the infused side only. Further studies
are in progress in an attempt to provide regional protection to the
bone marrow. Such procedures may eventually enable larger doses
of IUdR to be administered to the patient and therefore to the tumour
without the production of serious side effects.
IUdR inhibits the utilisation of TMP and fluorodeoxyuridine
inhibits the formation of TMP. It was therefore thought that these
drugs might act synergystically. Studies undertaken by Young et al,
(i960)showed marked potentiation of IUdR by the addition of fluorodeoxy-
uridine but since toxicity to normal tissues was increased to an equal




EFFECTS OF THE HALOGENATED PYRIMIDIKKS
ON THE THRESHOLD OF RADIATION SENSITIVITY.
INTRODUCTION.
One of the major obstacles in the therapeutic measures aimed
at destroying tumour tissue is teat in many instances it is impossible
to selectively destroy the neoplasm without at the same time producing
considerably injury to the normal tissuesj that is to say the
therapeutic ratio, which is the ratio of the effect on normal tissue
to that on tumour tissue, is low. The tolerance of normal tissues to
either chemotherapy or radiotherapy therefore usually becomes the
limiting factor in the total dose of drug or X-rays teat it is
permissible to administer. In recent years with tee advent of new
forms of radiotherapy it has been possible to direct ionising
radiations to strictly localised areas with very little scatter to tee
normal tissues. Sooner or later, however, the limit of tolerance
is reached by the overlying tissues and this form of therapy has to
be abandoned. If the tumour tissue could selectively be made more
sensitive to ionising radiation while the overlying tissues remained
unchanged the effective dose of radiation that could be administered
would be considerably increased. Moreover, by lowering the threshold
of radiation sensitivity in the tumour tissue, certain neoplasms teat
are usually considered resistant to irradiation might become amenable
to such therapy.
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One possible approach to the solution of this problem is
the combined use of chemotherapeutic agents with radiotherapeutic
measures and prominent in studies in this connection are the
halogenated pyrimidines. The effect of combined therapy with
antimetabolites and x-irradiation may be additive or it may be
synergistic so that the combined effect is greater than the simple
addition effect of each agent. The aim of therapy is to achieve
a synergistic effect and/or an increase in the therapeutic ratio.
If the two agents are synergistic and also produce an increase in
the therapeutic ratio then therapeutic synergism is said to exist.
IN YIThO STUDIES;
Using a thymine deficient strain of E.ooli Greer (i960)
demonstrated that if the organisms were allowed to grow in the
presence of 5-bromuracil with consequent replacement of a considerable
portion of the thymine in the UNA by the analogue then their
sensitivity to the ultraviolet irradiation was markedly increased.
Szybalski and his associates (Djordjevic and Szybalski, i960;
Szybalski and Djordjevic, 1959; Erikson and Szybalski, 1961) with
cultures of human cell lines have shown that incorporation of iodo-,
bromo- or chlordeoxyuridine into the DNA increases the sensitivity
of the cell to ultraviolet light and x-irradiation by anything up to
22 times. The chlorine and bromine compounds may be incorporated
into DNA with replacement of up to 30 to 60 per cent of the DNA-
thymine without loss of viability of the cells provided such replace¬
ment is achieved gradually during many successive reproductive cycles.
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Greater incorporation of the preformed thymidine analogues could
be obtained if de novo synthesis of TMP was blocked by the addition
of fluorodeoxyuridine to the medium. These authors attributed the
greater viability of the cells in the presence of broao- and
chlorodeoxyuridine than in the presence of lUdK to the fact that
van der Waal's radius of the methyl group more nearly approached
that of the bromine and chlorine than it does that of the iodine
atom.
The chlorine compound was less effective than the other two
in lowering the threshold of sensitivity both to ultraviolet light
and to x-irradiation. IUcLR brought about the greatest reduction
in the threshold of sensitivity to X-rays but bromodeoxyuridine was
more effective when ultraviolet light was employed (Erikson and
Szybalski, 1961)•
After many replications had occurred in the presence of
these analogues a large proportion of TMP in both strands of the
double helix of DNA had been replaced. This "bifilar" labelling,
the authors believed, produced in the cells a reduction in the
threshold of radiation sensitivity after exposure either to ultra¬
violet light or to x-irradiation* Moreover, they suggested that
the compound must be present in both strands of the DNA since if
such radiosensitisea cells were allowed to undergo a single
replication in the absence of the analogue restoration of their
former relative resistance to radiation injury was observed
(Djordjevic and Szybalski, i960)• Other workers using Chinese
hamster (Mohler and Elkind, 1961) or human bone marrow (Humphrey et
U8,
al, 1961) cells have also found potentiation of radiation
sensitivity following exposure to bromodeoxyuridine,
The question arises as to whether sensitisation might be
dependent upon the presence of phosphorylated derivatives of the
analogue in the cytoplasm rather than in the DNA and the fact that
one reproductive cycle in the absence of the analogue restored
resistance to radiation injury does not in itself preclude this
possibility since this would also most probably lead to a marked
diminution in the halogenated nucleotides contained within the
cytoplasm. Szybalski and Opara-Eubinska (I96I) have produced some
evidence to show that DNA is the principal determinant of cell
radiosensitivity, at least in bacterial cells. They grew Bacillus
subtilis organisms in the presence or absence of bromodeoxyuridine
and found that the incorporation of the analogue resulted in similar
increments of radiation lethality of intact cells and of decreased
inability of DNA extracted from these cells to transform indole-requiring
cells to prototrophy. These experiments suggest that in intact bacterial
(and mammalian by close analogy) cells DNA is the principal and
indispensable target of lethal ultraviolet and X-ray effects. Radiation
effects on other cellular activities such as observed inhibition of new
enzyme (protein) synthesis would thu3 seem to represent only secondary
expressions of radiation damage to DNA structure and biological
function. Kaplan et al (19&2) have also carried out bacterial
studies indicating that the radiosensitivity conferred by the
halogenated pyrimidines is dependent on their incorporation into the
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DMA. They showed, for example, (as did Djordjevic and Szybalski,
i960) that incorporation of bromocdeoxyuridine into DNA was
progressive with time and the degree of radiosensitisation also
increased progressively in a similar manner to a plateau at about
40 to 50 per cent substitution of bromuracil for thymine. Other
analogues which were not incorporated into DNA lacked radioseniitisijag
activity. These authors, however, did not find absence of
radiosensitisation with unifilar labelling of DNA but found it to
be 50 per cent of that seen when both strands were labelled. They
were unable to offer any definitive explanation of the mode of action
of the halogenated derivatives in this respect but DNA-oontaining
bromodeoxyuridylic acid has been shown to have a slightly higher
melting temperature than its normal counterpart (Kit and Hsu, 1961).
The effect of the halogen is presumed to be either in the
strengthening of the hydrogen bonding with adenine or in changing the
interaction of DNA with cation since the melting temperature is a
function of cation concentration. As Lajtha (i960) points out
most primary lethal actions of radiations are due to inhibition of
mitosis, chromosome damage, or gene mutations. It would therefore
seem reasonable to examine chromosome morphology of "radiosensitised"
cells. Djordjevic and Szybalski (i960) found that chromosome
morphology was not significantly altered after incubation of the
cells with levels of bromodeoxyuridine which conferred radiation
sensitivity} only at very high levels which noticeably affected cell
viability was chromosome damage noted. Humphrey et al (I96I), however,
cultured an in vitro strain (LET-1) of Lettre/ mouse ascites tumour
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and L-P59 cells in the presence of low concentrations of bromodeoxy¬
uridine (5 and 10 ug/al.) for pex'iods of time varying from 6 to 96 hours.
1'hese cells were then subjected to x-irradiation and chromosomal
damage observed at raetaphase and anaphase at various times after
irradiation. The observed changes indicated that the cells were
approximately twice as radiosensitive as that of the control cells.
The maximum increase in sensitivity was observed when the incubation
period was 24 hours with LET-1 cells and 48 hours with the L-P59 cells
prior to irradiation.
mmSL SgUPItgi
Krias and hevea (1962) have demonstrated a greater inhibition
of post treatment growth curves of ihrlich ascites cells in vivo when
X-rays were administered following a course of bromodeoxyuridine than when
X-rays were administered alone. Berry and Andrews (1961) treated
mice with the ascites form of mouse transplantable leukaemia with
ICdS or bromod©oxyuridine and/or x-irradiation. At doses of 300
mg./kg./day for 4 days lUdE alone did not affect the number of
leukaemio cells required to produce a 50 per cent take in a group of
recipient mice of the same strain; but this dose markedly enhanced
the radiation effects i.e. brought about a marked reduction in the
number of cells reproductively intact after a single dose of X-rsy.
The amount of radiation potentiation was proportional to the dose of
XUdit administered. Bromodeoxyuridine alone produced a modest inhibition
of tumour cell reproductive capacity but also potentiated the radiation
effects at low dosage levels of the drug.
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CLINICAL STUDIESi
Kligoraan (i960) reported the results of combined XUdR
therapy with irradiation on hinsane carried out at Yale University.
Patients were treated for 5 or 6 days successively in a dose of
100-120 mg./kg. over a period of several hours. Of the nine patients
treated with IUdR and radiotherapy 6 were available for evaluation
and of these, 2 were thought to have shown definite potentiation to
X-ray therapy. The same author also reported cm twenty patients that
were treated with fluorouraoil in combination with radiotherapy and in
general these patients did not show regression superior to that seen
with X-rays alone but wore superior to the drug alone. There was,
however, on® exception; a patient with multiple cervical and supra¬
clavicular nodes secondary to buccal carcinoma had one node treated
with 2,500 rads in 5 days and a second node was treated with
fluorouraoil and X-rays simultaneously. Marked regression of the
latter node was seen but the one receiving X-rays alone did not
change. r'oye et al (i960) reported rapid and significant regression
in 12 out of 18 patients receiving a combination of X-rays and
fluorouracil when the X-rays were given over 12 days (2,000 rads)
and the fluorouracil given in a dose of 90rag.Ag, over the first
5 days. Three others showed moderate regression. One patient with
bilateral lung metastases from an embryonal cell carcinoma of the
testis had the right lung treated with combined therapy and the left
lung with X-rays alone three weeks later. Only slight regression
occurred in the left lung but complete regression occurred in the right
lung. Veraund (i960) treated 20 patients in a random manner with
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fluorouracil either alone or in combination with X-rays but he found
no difference in the mean survival of the two groups. Fletcher (i960),
however, found that in patients with head and neck carcinoma who had
received fluorouracil, regressions took place at the same rate with
X-rays in a dose of 6,000 rads in 6 weeks as when X-rays in a dose of
6,000 rads in 4 weeks were given to patients who had received X-rays
alone. Krant et al,(l96l) reported :s results in humans with various
"radioresistant" tumours when given broraodeoxyuridine alone in a
dose of 15 mg./kg./day over a period of 4-10 days and followed by
irradiation of the tumour. No toxicity save for a metallic taste
was noted, When possible, prior to or after combination therapy
radiation therapy alone was given in order to compare the results in
the same patients. In 4 patients so treated definite responses
"probably attributable to sensitisation" were observed in three (one
patient with a carcinoma of the stomach, and two with carcinoma of the
lung). The fourth patient with a testicular tumour responded to
X-ray therapy alone given later as well as he did to the combination
therapy.
DISCUSSIONt
The radiosensitising effect of the halogenated pyrimidines
and also certain other drugs such as actinomycin D., hormones and
alkylating agents opens up new possibilities for seleotive
potentiation of the radiotherapy of looallaed tumours. The halogenated
pyrimidines acting as thymine or thymidine analogues are of particular
value in this respect for owing to their utilisation for the synthesis
of new DNA, they have a selectivity of action for dividing cells.
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With the advent of new devices for the delivery of strictly
localised irradiation it then becomes possible to cause regression
of the tumour without interfering with actively dividing normal
cells in other areas of the body such as the bone marrow and
gastrointestinal tract.
Much more work needs to be done for the proper evaluation
of these compounds as radiosensitising agents in man. Many of the
cases treated with combination therapy have been inadequately
controlled. Each patient should serve as his own control whenever
possible and patients with such lesions as bilateral pulmonary
carcinoma or multiple metastatic skin nodules or lymph nodes are
most suitable. In 3uch patients a course of the drug may be
administered systemically and selected tumours irradiated afterwards
and compared with similar non-irr&diated lesions in the same patient.
If no such lesions are present the following steps should be taken.
(1) Irradiation of the lesion followed by an observation period of
sufficient length for the full effects of radiation to be noted
(e.g. one month). (2) A course of the drug in question may then be
given and a further period of time allowed to elapse for the
evaluation of drug therapy alone. (3) This can finally be followed
by combination therapy and a compar ison:made with re suits achieved
by either treatment alone.
Another possible approach to this problem is the implantation
of tissue from the primary tumour in multiple 3.1tes under the skin of
the arms so that multiple subcutaneous nodules of comparable nature
develop. These can then be treated with combinations of therapy in
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varying dosages with certain nodules serving as controls. This
procedure, however, raises ethical as well as considerable technical
problems. More work is required also to determine which techniques
of administration of the drug will facilitate its incorporation into





A brief account of the aims of the investigations that
were undertaken and the methods employed is given below.
SECTION 1. IUdR had been shown previously to inhibit the synthesis
of DNA-thymine (prusoff, 1959c&"d 196Qi. Experiments were,
therefore, undertaken to determine at which point or points on
the biosynthetic pathway IUdR exerted its inhibition. Cells from
various sources were incubated with either tritiated thymidine
(%-thymidine ) or carbon labelled formate (^C-forraate) in the
presence of IUdR. The thymine nucleotide fractions were then
extracted and separated by means of chromatography. The total
radioactivity in each fraction was determined and compared with
that in control cells in which no IUdR had been added. The specifio
activity of DKA-thymine was also determined and compared with that
in control cells in a similar manner.
SECTION II. The inhibitory effects of lUcLR and ICcLR on the biosynthesis
of thymine nucleotides and DNA-thymine were compared using similar
techniques to those in Section I. In addition, their relative
ability to inhibit the growth of micro-organisms and solid tumours
in animals was also determined.
SECTION III. The ability of deoxycytidine to increase the rate of
biosynthesis of the thymine nucleotides and DNA-thymine was
investigated over periods of time ranging from 0.5 rain, to 240 mins.
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Cells were inc ib.it^d with ^C-formate and the radioactivity in the
various fractio_s analysed usin^ the same techniques as in Section I.
The atility of deo:r,Tc;y tidine to reduce the inhibitory effects of IUdR
was also studied.
In fijurc 4 is shown the overall experimental procedure that
was adopted for the incorporation of radioactive thymidine or formate
into the phosphorylated derivatives of thymidine and EhA-thymine of
mammalian cells and the subsequent isolation and separation of these
various fractions.
DIAGRAM OF EXPERIMENTAL PROCEDURE FOR ISOLATION
AND SEPARATION OF THE PHOSPHORYLATED DERIVATIVES
OF THYMIDINE AND DNA-THYMINE
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STUDIES '''"IT1'? r'WLI,'!" CELLS.
Nutrient Buffer Solutions:
One of two nutrient buffer solutions was employed and both
were found to be equally satisfactory.
(a) Totter's Modification of Chambers Solution, (Totter, J.E., 1954:
(Chambers, E., 1943).
A solution of the following composition was prepared.
Potassium Chloride 2.6 g.
Sodium Chloride 0.78 g.




The pH was adjusted to 7.5 and the volume made up to 100 ml. with
distilled water.
This solution was diluted 5 times before use.
(b) Krebs III Buffer Solution. (Krebs, H.A., 1950).
Thi.3 solution was prepared as follows:-
0.9% Sodium chloride 95 parts
1.15/1 Potassium chloride 4 "
0.11 K calcium chloride 3
2.111 Potassium dihydrogen
phosphate 1 part
3.82$ Magnesium sulphate 1 part
(Kg. S0;+ 7 H20)
1.3,1 Sodium bicarbonate 3 parts
Sodium phosphate buffer 3 parts
(100 parts 1.78- Na^LPO^
2 H20 + 25 parts 1.381
Na H2P04 H20)
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0.16 ii bodium pyruvate 4 parts
0.1 k wodium furuarate J n
0.16 L Saaiuffi-L-^iutaa&te 4 "
0.3 k (5.4^) glucose 5
The pli was adjusted to 7»2
Both solutions were stored at -10°C until required Tor use.
Kaoioactxye 1 atarialst
The experiments were carried out using one of the following
radioactive materials.
(a) sodium ^O-formate with a specific activity of 3 Per V
(b) thymidine with a specific activity of 50 pc per p: 'ml.
. (ntiae taooll to s:
Xououecayuridine or iododeoxyoytidine was dissolved in
hrebs I1a buffer solution (pH 7.2) or in water and the pH adjusted
to 7.5. The final concentration of the solution used was 5 fiM/ntl,
as oxyc.v tioinc;
This metabolite was employed in some experiments. The
solution was at a concentration of 100 ph/'ml.
OX--,aX.-- .-.Alh
u-rowtn fceoiux lor .,-ueptococous ^aecaiis .-dl 2043; •
Double Strength.
Dextrose anhydrous 40.0 g.
Na2 citrate 2H?0 63.O g.
K^HPO^ anhydrous 6.0 g.
Acid hydrolysed casein 1.0 g.
D-L Tryptophane 800 sag.
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Adenine sulphate 50 mg.
Guanine hydrochloride 5.0 mg.
Xanthine (monosodium salt) 200 mg.
L-Asporag ine 600 mg*
L-cystine 500 rag.





Salt solution (see below) 10*0 ml
The final pli was adjusted to 6*8 snd distilled water added to $00 ml.
Vitamin Mixture (Double strength)»
1) Pyridoxins hydrochloride 4*0 mg*
Thymine hydrochloride 4*0 mg.
Calcium hydrochloride 8*0 mg*
Nicotinio acid 8.0 mg.
Dissolve in 200 ml* distilled water* Add 200 mg* biotin,
2) 10 mg* riboflavins dissolved in 200 ml* 0*02 M, acetic acid*
3) Add 40 ml* sodium acetate buffer solution (pH 4*5)*
4) Adjust volume to 1 litre with distilled water*
Acetate Buffer pH 4*5*
Glacial acetio acid 18*75g(19.8 ml.)
Sodium acetate 38.65 g.
Adjust volume to 500 ml* with distilled water*
Salt Solution*
MgSO^ H20 1.5 g.
NaCl 1.0 g.
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Fe S04 7 ^20 1.0 g.
750 mg
Adjust pK to 6.8. Make up volume to 500 ml. with distilled water.
To the medium folic acid, thymidine or thymine was added
in a concentration sufficient to allow half maximum growth of the
STUDIES WITH MAMMALIAN CELLS.
Preparatlor.s of cell suspensions.
All cell suspensions from animals were prepared in the cold.
White cells from human leukaemic blood were separated at room
temperature.
(a) Mouse Tumours.
1. The Ehrlich Ascites Tumour was maintained in DBA/2 micq, 5 or
6 days following the intraperitoneal innoculation of mice with tumour
cells, ascitic fluid was collected from a suitable number of mice and
pooled in a graduated centrifuge tube (40 ml.) which contained a few
ml. of the modified Chambers or Krebs III nutrient buffer solution.
After centrifugation the cells were washed once in normal (0.9 P®*1
cent) saline and then resuspended in Chambers or Krebs solution to
form a 25 per cent suspension,
2. L-5178Y lymphoma.
The mice bearing the lymphoblastic leukaemia L-5178Y were
ADR x DBA/2 F1 Hybrids i The Y strain of leukaemia L-5178 was
developed by G.A. Fischer and J.J, Jaffe from a single cell, isolated
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In vitro and grown initially in a medium which has been described by
G-.A. Fischer and A.D. Welch (1957). These cells were prepared in
the same way as the Ehrlich ascites cells.
(b) The Walker Rat Tumours.
Walker carcinosarcoma 256 was implanted subcutaneously in
male weanling albino rats. After 10 days the tumours were removed and
homogenised in Krebs III buffer. After centrifugation the cells
were resuspended in buffer to form a 25 per cent suspension.
(c) Calf Thymus.
Fresh normal calf thymus tissue was homogenised in Krebs III
buffer solution and a 25 per cent suspension made as described above.
(d) Human Leukaemias.
Preparations of cells from human leukaemias were made
according to the method described by Walford et al (1957). Whole
blood was mixed with 25 per cent of its own volume of 6 per cent
dextran solution and allowed to stand at an angle of 40 degrees at
room temperature for 40 minutes. The white cell layer was then
pipetted from the top and after centrifugation the cells were washed
with 0.9 per cent saline and a 25 per cent suspension of cells in
Krebs III buffer solution was prepared.
Incubations.
(a) Effect of IPdR or ICdR on the utilisation of ^H-thymidine or ^"C-
formate for the biosynthesis of the phosphorylated derivatives of
thymidine and UNA-thymine.
Incubation mixture consisted of 1 ml. of 25 per cent
suspension of cells, horse serum (0.2 ml.) iododeoxyuridine or
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iododeoxycytidine in a concentration of 5 jJ-Tl/ml• or 0.5 p^/ml.
(1 ml.) thymidine (0.1 ml.) or ^C-formate (0.1 ml.) and Totter*a
modification of Chambers solution or Krebs III buffer solution to
2.3 ml. The control incubation mixtures contained no antimetabolite
but were replaced by an equal volume of the appropriate buffer
solution.
The incubations were carried out under an atmosphere of air
in a Dubnoff metabolic shaker at 37°C for varying periods of time
up to 2 hours after which "the reaotion was stopped by centrifugation
in the cold. The cells were then washed twice with saline in the
cold to remove most of the excess ^"C-formate or hi-thymidine•
(b) Effect of deorycytidine on the utilisation of "^C-formate for
the biosynthesis of the phosphorylated derivatives of thymidine
and DNA-thymine.
The incubation mixture (final volume 7*2 ml.) contained packed
cells (0.75 ®1*)» horse serum (0.6 ml.), ^C-formate (9 pc;3 pM) in
the absence or presence of deoxycytidine (30 pTi) and Krebs III buffer
solution. The incubations were conducted in 50 ml. beakers under an
atmosphere of air in a Dubnoff metabolio shaker at 37°C.
In the first experiment the cells were examined after 5
minutes and subsequently at 10, 15» 30» 60 and 120 minutes.
In the second experiment the cells were examined after 0.5
minutes of incubation and thereafter at doubling intervals of time
up to 4 hours. The reactions were terminated by the addition of
trichloracetic acid (0.5 ml., 100 per cent).
d3*
isolation of the phosphoryl&ted derivatives of thymidine.
Tiro methods nr« employed but fee first to be described was
found to bo generally bettor*
(a) Trichloracetic /old Extraction*
All reactions were performed at 0 to 4°C. The washed or
froson Mils were suspended to ice-cold (triohloraootio acid) (5 per
cent* 5*10 ml.) for 20 minutes* Following centrifugation the
TCA-extraotion was repeated and the supernatant fractions were
combined. The TCA was removed by e ther-extreotion and fete residual
ethsr was removed by bubbling nitrogen through the solution* The
pH was adjusted to 7*5 * 0*5 or to 10*5 * 0*5 *ith NaCM (0*2 17)
depending cm the method used for separation of the nucleotides (sse
below).
(b) Perchloric Acid Extraction.
fashed or frosen cells were suspended in 5 *1» ice-cold
perohlorio eoid (0*5 M) for 15 minutes* After eentrlfugatlon the
supernatant was decanted and adjusted to pH 5-10 with KQH (2 17)
using phenolphthalein as an indicator* After centrifugaticn the
supernatant was deoanted*
Separation of thymidine and its Phosohorylated derivatives.
This was attempted by a variety of procedures. Curing the
course of this investigation one new technique was devised by the
use of ion exchange paper*
(a) Column Chromatography.
Three methods were tried and each is described below*
(1) Cewex-1 formate (x 8) columns 1 cm. in diagnotor and 10 cm*
long were employed. They were prepared for use by washing with
a solution of formic acid ( 6 N) and ammonium formate (2 N) followed
by water. The thymidine nucleotides were adsorbed on to the
column at pH 10-11 and thymidine, TMP, TCP, TIP separated by elution
with formic acid (0.1 N) and ammonium formate (0.3 IT, 0.6 N and 2 N
successively). Thymidine, TMP and TTP (0,2 jiM.) were added to the
extract and each fraction was considered to be completely recovered
from the column when the appropriate marker and radioactivity could
no longer be detected in the eluate. Each fraction was contained
in about 50-100 ml, of eluate,
(2) Dowex-1 formate (x 4) columns, 1 cm, x 25 cm, were employed.
To these columns a perchloric acid extract prepared as described
above was applied at pH 9-10. Gradient elution using water (500 ml.)
and 1 M solution of ammonium formate (500 ml.) was carried out.
After eluting with 500 ml., the upper reservoir was filled with
2 M solution of ammonium formate (pH 5, 500 ml,). The fractions
were collected by means of a fraction collector and each fraction
was contained in about 50-70 ml, recovered from the column after
eluting with approximately 50, 285, 400 and 600 ml, of fluid with
respect to thymidine, TIP, TCP and TTP respectively,
(3) EEA Cellulose Columns,
This method was described by Weissman et al (19^0) and
generally proved to be the most useful method and easiest to execute;
8x1 cm, columns were used. The cellulose was washed with 50 m,
0,5 N HC1 and 125 ml* H20. The acid soluble extract was then applied
to the columns at pH 7-8 and thymidine, TMP, TCP and TTP eluted off
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successively with H20, 0.01 NHC1, 0.05 NHC1 and 0.5 HHC1 respectively.
The volume of e?ch solution required to recover all the radioactivity
in each fraction was approximately 50-70 ml. The marker substanoes
could be recovered consistently in the expected fraction and the pH
of the extract when applied to the columns did not appear to be
critical.
(b) A New Method usinr Paper Chromatography.
Thymidine and its various phosphorylated derivatives have
been readily separated from each other by column chromatography
(see above) (Hurlbert et al, 1954} Schneider, 1945). However, it
has been difficult to obtain such clean separations using paper
chromatography (Bollum and Potter, 1959). Although thymidine and
TMP have been readily separated on paper, there was appreciable
overlapping of TIP and TTP and the results could only be interpreted
in a semiquantitative measure. Paper chromatography is often
desirable because this method permits the separation of microquantities
of materials and is very convenient when dealing with a large number
of samples.
The method now to be described was developed during the
execution of the work reported in this thesis and gives efficient
separation of thymidine, T!5P, TDP and TTP by paper chromatography
using Whatman cellulose paper AE30. Prior to the adsorption of a
solution composed of a mixture of thymidine, TMP, TDP and TTP, the
paper strip was washed successively with formic acid (0.1 N), ammonium
formate (0.5 N) and water for 24 hours. The first solvent, formio
acid (0.01 N), was used to separate thymidine from the other
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constituents. In this solvent system thymidine movsd with the
solvent front which was permitted to travel almost to the end of
the paper. The ohromatogram wa3 allowed to dry "before elution with
the second solvert system, (ammonium formate 0.06 N, pH 5.0), which
was allowed to flow two thirds of the distance transversed "by the
first solvent system. The various components were located with the
aid of an ultraviolet lamp (figure 5) and readily eluted in HCl (0.1 N)
with essentially 100 per cent recovery. The minimum quantity which










Diagram showing the distribution of the thymidine nucleotides following
chromatographic separation using Whatman oellulose paper AE30.
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Dlsousalon on the relative merits of the methods used for the
separation of thymidine and its phosphorylated derivatives.
The most generally useful method was found to be that of
Weissman et al (i960) using cellulose columns. It provided a means
of rapid and easy separation of the various fractions and the columns
were easily regenerated by washing with water. The fractions could
be eluted from the column in a fairly small volume which allowed the
radioactivity in 0.2 ml. aliquot to be counted readily by means of a
scintillometer.
The use of formate columns with manual elution was tedious and
the fractions were contained in somewhat larger volumes. This
sometimes necessitated the concentration of the fractions in order
to obtain significant numbers of counts above background when the
samples were examined for radioactivity. This in turn led to
further difficulty because the high concentration of ammonium formate
gave rise to self absorption if the counting was done by means of a
continuous gas flow counter using stainless steel planchettes and to
quenching if the scintillometer was used. A further objection was that
the TCA-extracts when applied to the column tended to produce hubbies
in the resin and so gave rise to chanelling. This could be overcome
by the use of perchloric acid extractions.
When formate columns were used in conjunction with gradient
elution and with perohloric acid extracts the results were very
satisfactory and the fractions were recovered in reasonably small
volumes. It was found generally, however, to be more time consuming
than the method employing cellulose columns.
The paper chromatographic method was found to be satisfactory
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unless there was a high concentration of radioactive thymidine
present, when some trailing over the paper occurred. Moreover, it
was again more time consuming than the use of the cellulose columns.
The latter method was therefore adopted for the majority of the
experiments and proved to be very satisfactory.
Determination of total radioactivity in each nucleotide fraction.
Whereas complete separation of excess ^H-thymidine from the
nucleotide fractions could be readily achieved, difficulty was
encountered in attaining the removal of excess "^C-formate. Hence,
in studies with ^H-thymidine, the total radioactivity in each
nucleotide fraction was measured in a windowless flow counter
(following the plating of appropriate aliquots in the centre of a
stainless steel planchette) or in a Packard liquid scintillometer.
14
In all studies with C-formate, because of the known contamination
with non-thymine radioactive substances in each of the separated
fractions composed of the individual thymine nucleotides, the
following procedure was adopted. Subsequent to the addition of
thymine (1 jimole) to each fraction, the solution was evaporated to
dryness and the residue was digested with 0.2 ml. concentrated
perchloric acid for 1 hour in a boiling water bath, in order to
hydrolyse the thymine-containing nucleotides to free thymine. After
digestion the solution was diluted 10 times and neutralised with KOH.
Thymine was separated from other bases in the supernatant and from C-
formate by paper chromatography in the isopropanol-hydrochloric acid
system; this separation was followed by re-chromatography in the
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butaaaol-ammonia system. Following elution of the thymine from the
paper its concentration was determined, by measuring the extinction
in a Beckman ultraviolet spectrophotometer and the radioactivity
was measured in the manner described above. This information
permitted the calculation of the amount of radioactivity in 1 umole
of thymine and hence the total amount in each fraction associated
with the thymine-containing nucleotides.
Nucleic Acid Extraction.
(a) thymidine incubations;
The procedure of Schneider was used. A hot TCA extract using
5-10 cc. of 5 Pe*" cent TCA at 90°C for 30 minutes was made on the
cells following complete extraction of the low molecular weight
compounds by cold TCA. The amount of radioactivity present in an
0.2 ml. aliquot was then determined in a scintillometer or continuous
gas flow counter (after removal of the TCA by ether extraction).
The specific activity of the BNA-thymine was then determined by
estimating the BNA content of the sample (see below).
, 14.
(b) C-formate incubations;
The nucleic acid extract was made as above and then evaporated
down to dryness. Hydrolysis with HCIO^ was performed, no additional
thymine having been added in this instance. DNA-thymine was then
separated by paper chromatography and the specific activity determined
as outlined above.
.Estimation of the BNA content of the Nucleic Acid Extract.
In these experiments the DNA content was measured by colour
reactions of the sugar component. A major difficulty of such methods
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is the calculation of the actual amount of DNA present from the
amount of reactive deoxypentose. Comparative results, however, were
all that were required for the experiments to be described. Two
methods were employed. The modified method of Dische (1930)
described by Burton (1956) and the Stumpf (1947) reaction. The
former method was found to be more sensitive but the latter was
easier to carry out and was sensitive enough for the relatively
large amounts of DNA involved,
(a) Modified Dische Teohnique.
This method depends upon the development of a blue colour
when diphenylamine in a mixture of acetic acid and sulphuric acid
reacts with sugar residues which were originally combined with DNA
bases (probably purines).
Diphenylamine reagent.
1.5 6* steam distilled diphenylamine was dissolved in
100 ml. redistilled glacial acetic acid and 1.5 ml. conc. H^SO^
added. The reagent was made up fresh before each experiment and
immediately before use 0.1 ml. of aqueous acetaldehyde in a
concentration of 16 mg. per ml. was added to each 20 ml. of the
reagent.
DNA Standard Solution.
40 mg. of a standard preparation of high molecular weight
DNA were dissolved in 100 ml. of 0.05 N NaOH. From this a working
standard was prepared in the following manner. Equal volumes of the
standard DNA solution and perchloric acid were heated for 15 minutes
at 70°C to hydrolyse the highly polymerised DNA and a fresh solution
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was prepared every 3 weeks#
Procedure#
To 0.96 ml. of the nucleic acid extract from which the
trichloracetic acid had been extracted by ether, was added 0.04 ml.
concentrated perchloric acid to give a final concentration of 0.5 N.
To this was added 2 ml. of the diphenylamine reagent. A blank tube
was prepared containing no DNA and 5 standard tubes containing the
working standard DNA solution in volumes ranging from 0.2 to 1.0 ml.
and 2 ml. diphenylamine reagent were prepared. The final volume was
adjusted to 3 ml. with 0.5 N perchloric acid. All tubes were set
up in duplicate and incubated at 37°C overnight for 16-20 hours. A
blue colouration developed depending upon the concentration of DNA
present and the colour intensity was read by measuring the optical
density against the blank at 600 raja. This was compared with the
values obtained with the standard DNA solutions.
(b) Stumpf Reaction.
In this method a pink colour develops when DNA is heated with
cysteine and sulphuric acid. To a test tube was added 0.05 ipli of
cysteine hydrochloride, an aliquot of the unknown solution (0.5 ml.)
and 5 cc. 70 per cent HgSO^. The mixture was stirred rapidly with a
glass rod and after standing at room temperature the optical density
was measured at a wave length of 490 mji. on the Klett-Summerset
spectrophotometer. A reagent blank was used to set the instrument
scale to zero and the results quantitated by means of a standard curve
obtained at the same time under identical conditions. The standard
material used was thymidine in amounts varying from 0 to*25 nig. per
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test tube and this was equated with a "unit" of DNA which was the
amount giving the same colour reactions as 1 mg. thymidine.
Preparation and incubation of cell free extracts from, mouse leukaemia cells.
Cells were harvested 6 days following the innoculation of
MR x DBA/2 F^ hybrid mice with L5178Y ascites cells. After
centrifugation the cells were washed once with normal saline.
Packed cells (3 ml.), buffer solution (0.05 M, pH 7*9) a^cL glass
beads (200 micron^ 7 ml.) were agitated for 20 seconds in a Nossal
vibrator. Following filtration through glass wool the filtrate was
centrifuged at 10,000 x g. for 10 minutes. Both the composition of
the incubation mixture and the conditions used were similar to those
described by Weissman et al (19^0)• The reaction mixture (1.2 ml.)
contained MgCl2 (35 /umoles), ATP (110 pmoles), tris buffer pH 7.9,
(110 ytmoles), %-thymidine (5 yic, 0.01 (omole), and various levels of
IUdR (0.G1, 0.1 and 0.5 praoles). The reaction was terminated after
incubation for 90 minutes at 37°C by the addition of TCA in a final
concentration of 5 per cent. The TMP fraction was then separated
using cellulose columns as described above.
In Vivo studies to test the inhibitory capacity of IUdR and ICdR on
tumour growth.
Female (AKR x DBA/2) hybrid mice, 6-8 weeks old and weighing
18-25 g. wsre used. The animals were fed Purina Laboratory Chow, and
drinking water was available ad libitum. Transmission of the
leukaemia which was maintained in the ascites form was accomplished
by a method modified after that of Lowenthal and Jahn (1932). One ml.
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of ascites fluid containing L5178Y tumour calls on the seventh day of
development was removed aseptlcally from a freshly sacrificed donor
mouse and transferred immediately to a test tube containing 9 ml* of
sterile hinger-Locke's solution* The solution contained approximately
3x10^ cells per ml* Each mouse was injected with 1 ml* of this fluid
subcutaneoualy into the right flank* Treatment with the drug (lUdH
or ICdK) was begun 24 hours later into individually weighed mice*
Various doses in a constant volume of 1 ml* per mouse were injected
intrapeil toneally once daily for 6 consecutive days. In each
experiment 10 mice were used to study the effeot of each dose level of
the drug while 10 mice which served as controls were given 1 ml* of
normal saline per mouse simultaneously* On the day following the
final dose each mouse was weighed, sacrificed and its tumour dissected
out and weighed. The average tumour weight of each group was compared
with that of the controls and the result was recorded in terms of
percentage inhibition of tumour growth*
ps iq^BmsMS* ■
The measurement of the ability of lUdii and ICdJk to inhibit the
growth of microorganisms was carried out by methods similar to the
microbiological assay methods employed for vitamin end folio acid.
Into each of 7 test tubes was measured 2*5 ml* of double
strength growth medium and to this was added the limiting growth
factor In the appropriate quantity to allow half maximum growth
(folio acid 0*5 ml*, 1.8 x 10***' pm/ml,, thymidine 0*5 ml*, .04 pa/ml.,
thymine 0*5 ml., *04 jan/al*)* antimetabolite (lUdB or ICdH) was
added in the following amounts to successive tubes 0*0; 0.25; 0*5} 1;
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2.5; 5 and 10 umoles and the final volume adjusted to 5 ol. with
distilled water. A blank tube containing no antimetabolite and a
further control tube from which the limiting growth factor w&s
witheld were also prepared. All experiments were performed in
duplicate.
The contents of all the tubes (other than the blank) were
inoculated with the test organism (Streptococcus faecalis ATCC 8043).
The tubes were incubated for 16 hours. The amount of growth depends
upon two factors: (1) the limiting growth factor in the medium and
(2) the amount of inhibition (or stimulation) induced by the analogue.
The turbidity of the contents of the tube is proportional to growth and
can be compared with the amount of growth in the tube containing no
analogue. The turbidity was measured with a KLett Summerson






EFFECT OF 5-IODO-2'-DKOXYURIDINE ON THE BIOSYNTHESIS OF THE
PHOSPHORYLATEL DERIVATIVES OF THYMIDINE AND DNA-THYUINE.
Introductioni IUdR has been reported previously to be an effective
competitive antagonist of the utilisation of thymidine for the
biosynthesis of the TIP portion of UNA (Prusoff, 1959b. and c; Prusoff,
i960 a. and b; Mathias and Fischer, 1959a. and b). Through a
limitation on the use of thymidine derivatives, formed from either
orotic acid or formate, the appearance of these precursors in DNA-
thymine was inhibited by IUdR (Prusoff 1959c. and 1960a). Thus,
both the exogenous and the de novo pathways concerned with the
formation of phosphorylated derivatives of thymidine were affected
by IUdR (or its derivatives). This analogue inhibited the reproduction
of mammalian (Prusoff, 1959b; Mathias and Fischer, 1959a. and bj Jaffe
and Prusoff, I96O; Cheong et al, i960) as well as of bacterial cells
(Prusoff, 1959c). Although it has been demonstrated that IUdR can be
incorporated extensively into the DNA-polymer (Prusoff, 1959b. and 1960b;
Mathias and Fischer, 1959a. and b; Jaffe and Prusoff, 19&0; Cheong
et al, I960; Eidinoff, 1959c. d. and e.), it was not established
that inhibition of cellular reproduction is causally related to
this observed biochemical event. The results shown below
indicate that the decreased incorporation of precursors into DNA-thymine
is a aresuit of a primary inhibition of thymidine kinase, TMP kinase,
or A-polyaerase, the specific site of the Inhibition being
characteristic of the cell typo#
Mouse Tumours - Lymphoma 151761 cells in vitro#
(a) vjth ^-thymidine as the precursor# In Table I and the
accompanying histogram are shown the results obtained from pre¬
incubation of 151761 cells with 1U&K for 15 minutes prior to toe
addition of thymidine. A seven-fold increase in the specific
activity of MA was observed in the presence or absence of IUdfi
when the incubation was prolonged from 0,5 hr# to 2.0 hr., although
at both intervals of time there was an identical degree of Inhibition
(78 per cent) by lUdk of the utilisation of thymidine for toe
biosynthesis of JDNA-thymine# In toe presence of to© analogue, both
at 0.5 hr. and at 2 hr#, there was a decrease of about 91- per cent
in the amount of radioactivity in toe combined nucleotide pools#
The decreased incorporation of %-thymidine into SNA-thymine appears
to be a result of an inhibition which occurred prior to the formation
of TMP# Two possible mechanisms of inhibition include a block by
lUdii of thymidine kinase or of the mechanism of transport of thymidine
into the cell# Support for the former hypothesis is described in
Page 82.
Because thymidine per se is not on the pathway for toe
biosynthesis de novo of TMP and since it had been shown previously
(Prusoff, 1960a) that IUdR inhibits toe appearance of either orotic acid
or formate in the thymine of DNA, but not the utilisation of orotic
acid for the biosynthesis of DNA-oytoaine or of BKA-pyrlmidines, it
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The effect of pro-incubation of II'dft on the utilisation of
- *H-thymidine for the biosynthesis of TIP, TL-P, TIP and DNA-
thymine by murine L>173Y leuJcaemio cells in vitro *
Distribution of radioactivity.






































• betails of incubation conditions are described in the text.
v Cells were pre-incubated for 15 min. with lUdK (2 /oaoles per ml.)
prior to the addition of hi-thymidine (0.04 jnmoles per ml.).
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50 - 10 -
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10 2 - |
7771 Y7i 1 V71 i
TMP TOP T1rp TMP TDP T1rp DNA-T DNA-T
0-5 HR INCUBATION 2-0 HR INCUBATION 0-5 2-0
70.
was apparent that IUdR must exert its inhibitory effect at another
site, presumably after the formation of IMP.
In a second experiment it was hoped to create conditions
whereby the various phosphorylated derivatives of thymidine would
have a better opportunity of being formed prior to the development
of the inhibitory effect of IUdfi. In Table 2 and accompanying
histogram are shown the results obtained when IU&R was added to
the reaction mixtures before, after or simultaneous^with the
x
inclusion of ^H-thymidinej however, there was no significant
accumulation of radioactivity in any of the nucleotide pools
regardless of the time of addition of IUcLR. The variations in the
absolute amount of radioactivity in the total acid-soluble pool of
the control cells, as well as the different distribution of radio¬
activity among the nucleotides, as compared with the findings obtained
in the previous experiment, may be a reflection of a variation in
metabolic activity of different batches of cells. It was found
that the extent of inhibition of the incorporation of ^H-thymidine
into DNA-thymine varied inversely with the time of addition of IUdR.
Thus, the larger incorporation of radioactive thymidine into MA-thymine
was observed when the addition of IUdR followed pre-incubation with
thymidine for 15 minutes. It appeared that the nucleotide fractions
were rapidly formed during the 15 minutes interval prior to the addition
of IUdR, and that these radioactive pools, formed in the absence of
IUdR, were utilised subsequently for the formation of DNA-thymine.
Accordingly, the data suggested that the utilisation of ^H-thymidine
for the biosynthesis of DNA-thymine by L5178Y cells in vitro is
blocked by IUdR primarily at a stage prior to the formation of TMP.
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Table 2 rrd aeco^pg-nyin.'T Histogram.
Effect of time of addition of ^H-thymidine in relation to
IUcLR on the formation of TNP, TIP, TTP and DNA-thymine by
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(b) with ^C-i'oraate as the precursor.
for the reasons described above a study was made of the effect
of Ibdii on the formation of thymine-nucleotides derived from the
da novo pathway in which thymidine per se does not participate. In
Table 3 and its histogram are shown the effect of IUdJK on the
utilisation of ^-formate for the biosynthesis of TMP, TAP, TTP
and BNA-thymine by L5178T cells in vitro.
In agreement with earlier studies (Prusoff, 1960a)f marked
inhibition of the utilisation of format® for the biosynthesis of
MA-thymine was observed. There was no inhibition in the
conversion of TDP to TTP, since in the presence or absence of IUdB
there was about a two-fold increase in the amount of radioactivity in
the TTP fraction, sa compared to that in TBP, Comparison of the
TMP and TDP fractions revealed a 100 per cent increase in the amount
of radioactivity in the TDP-fraction of the control calls, a 50 per
cent increase in the presence of the lower concentration of lUdli,
but no increase in the TDP fraction at the higher level of II!dh.
In fact, in the presence of the higher concentration of XUdR, the
amount of radioactivity of the TDP fraction decreased to }6 per
cent of that present in the TMP fraction.
This latter inhibition appears to be a reflection of the
decreased formation of TMP, Although a reproducibly larger amount of
radioactivity appeared in the TMP fraction in the presence of the
higher level of HJdfi, this probably reflects an inhibition of TMP
kinase with consequent piling up of TMP behind the block. At the
lower level of lUdJh no inhibition of TMP kinase was observed;
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Table 3 end ncconnanylnp. histogram.
The effect of XUda. on the utilisation of ^C-formate for the
biosynthesis of T,1P, TIP, TTP and INA-thymine by 15178Y





























































hence, the relative distribution of radioactivity among the TMP, TDP
and TTP fractions was similar to that of the control. Thus, almost
three times as much radioactivity is observed in the TDP and TTP
fractions derived from cells incubated with the lower concentration
of IUdR, as compared to those derived from the higher level of IUdR.
The decreased formation of TMP by L5178Y cells in the presence of
lUdJR may be related causally to an inhibition of the thymidylate
synthetase reaction. In support of this it may be stated that in
the case of another thymidine analogue, bromodeoxyuridylic acid,
Flaks and Cohen (1959)» using a cell free system, observed some
degree of inhibition of this reaction although, as would be expected,
the effect was extremely small compared with the inhibition caused by
fluorodeoxyuridylic acid.
Cell-free extract of L5178Y leukaemia cells:
(a) With ^H-thymidine as the precursor -
A cell-free extract of mouse L.5178Y cells was; incubated with
%-thymidine in the presence of various amounts of IUdfi. The results
are shown in Table 4 and depicted graphically in Figure 6, At a
molar ratio of IUdR to thymidine of 1:1, no decrease in the formation
of TMP was observedj at ratios of 10:1 and 50:1, inhibition was
observed to the extent of 55 and 57 per cent, respectively. Thus,
the decreased utilisation of ^H-thymidine in the presence of IUdR by
the corresponding whole cell preparation described above may be
explained by the observed inhibition of thymidine kinase. Whether
or not there is in addition, any effect on the mechanism of transport
of thymidine into cells was not investigated.
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Table 4 and Figure 6.
affect of Ilidii on the phosphorylation of thymidine
in a cell-free preparation of murine leukaemia
L3178T cells,
Concentration IMP,






* Amount of lUdh in reaction mixture (1,2 ml.) which
contained thymidine (0.01 paole, 0.5 pC). Details
are described in text.
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Murine Ehrlioh ascites carcinoma cells in vitrot
(a) With ~^H-thymidine as the precursor -
In contrast to the observations made with L5178T cells, IUdR
exerted no inhibition in the Ehrlich ascites carcinoma cells, with
respect to either the transport of thymidine into the cells or
its subsequent phosphorylation by thymidine kinase (See Table 5 end
its accompanying histogram). In addition, there was no inhibition
of the conversion of TKP to TCP or of TDP to TTPj rather, there
appeared to be an accumulation of cold acid-soluble nucleotides,
particularly at the triphosphate level. In agreement with previous
studies, there was a marked reduction in the specific activity of
DM-thymine. Thus, the block of the utilisation of thymidine
appears to be at the triphosphate level in these cells.
Calf Thymus:
(a) With ^H-thymidine as the precursor -
It was of interest to determine at which site or sites
inhibition of the utilisation of thymidine occurred in normal
cells, such as the lymphoid tissue of calf thymus. The results
are shown in Table 6 and its histogram. Although there was a 50
per cent decrease in the formation of TMP in the presence of IUdR,
a more marked inhibition was observed in the phosphorylation of TKP
to TDP. Based on the relative amounts of radioactivity in the TKP
and TDP fractions of the control, the amount of radioactivity in the
TDP fraction derived from cells incubated with IUdR was only about
30 per cent of that which was obtained when thymidylic kinase was not
inhibited. There was no inhibition of the phosphorylation of TDP
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The effect of TJcL' on the utilisation of H-thymidine for
the biosyntnesis of IkP, TDP, TTP ana DNA-thymine by murine










































Table 6 end accompanying Histogram.
Effect of IUdR on the utilisation of 3I1-thymidine for the
biosynthesis of TMP, TDP, TTP and DNA-thymine by normal














None 23,000 10,000 980 536
IUdR 11,500 1,800 270 114























to TTP or of the utilisation of TTP for DNA-biosynthesis• The 80
pez* cent decrease observed in the specific activity of DNA-thymine
is probably a reflection of the primary inhibition of TMP kinase,
coupled with a less marked inhibition of either the uptake of
thymidine by the cells or of its initial phosphorylation to TMP.
Human Leukaemia Cells:
The inhibition of the synthesis of UNA-thymine brought about
by IUdR in various forms of human leukaemia is shown in Table 7.
(a) Chronic myeloid leukaemia cells - Peripheral leucocytes obtained
from two patients with chronic myeloid leukaemia were studied; the
results, shown in Tables 8 and 9 and their histograms, indicate that
the pattern of inhibition was similar to that seen with murine Ehrlich
*
ascites carcinoma cells. The uptake of H-thymidine by the cells
was not inhibited by IUdR, nor was its subsequent phosphorylations to
TMP, TDP and TTP; however, there was marked interference with the
polymerase reaction in which TTP is utilised for the biosynthesis of
UNA. Thus, in the presence of IUdR an increase in the amount of
radioactivity in the cold acid-soluble nucleotide pools was observed,
as well as a marked decrease in the specific activity of UNA-thymine#
(b) Acute monocytic leukaemia cells - The effect of lUdR on the
utilisation of 14C-formate and of %-thymidine for the biosynthesis
of the various thymine-containing nucleotides, as well as its effect
on the formation of UNA-thymine, were studied in white blood cells
derived from two patients with acute monocytic leukaemia#
The results (see Tables 10, 11 and 12 and their related
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the leucocytes of patient 1 was of the same order as that observed
with murine L517^ leukaemic cells; however, in patient 2 the effect
on the formation of T!T was much less marked. Although the pools of
TH? derived from nl-thymidine in the absence of IUdTt, in patients 1
and 2, were of essentially the same size, there was a marked difference
in the amount of radioactivity in the TDP fraction. In comparison
with the TI.IP fraction, the radioactivity in the TTP fractions in
either the presence or the absence of IUdR was relatively low.
Although there was little difference in the size of the TTP fractions
in the presence or absence of IUdR, there was a very marked decrease
in the specific activities of the UNA-thymine.
Accordingly, several sites of inhibition by IUdR and its
phosphorylated derivatives may be implicated in these cells; (1) a
partial block in the formation of TMP derived from the de novo
pathway; (2) a partial block in either the transport of thymidine
into the cell or of thymidine kinase (the exogenous pathway); and
(3) inhibition of DNA polymerase. The last site would appear to be
the most critical one in these cells with respect to the inhibition
of the biosynthesis of UNA*
(c) Cells of other types of human leukaemia: The effect of IUdR on
the utilisation of ^H-thymidine for the formation of TKP, TDP, TTP and
UNA-thymine, was examined in cells derived from one case each of
chronio lymphocytic leukaemia, and plasma cell leukaemia. In the
presence of the analogue a very marked inhibition in the conversion
of thymidine to TLEP wa3 observed with each type of cell, a finding
which might be attributed either to interference with the transport
95.
mechanism or to inhibition of thymidine kinase, Very little
radioactivity appeared in TCP, TTP or DNA, even in the absence of
HJdKj nevertheless, the amount of ^H-thymidine which appeared in
DNA in the presence of IL'cLR was markedly reduced.
Mechanism of "apparent" resistance to IUdR in vivo,
(a) Walker carcinosarcoma.
In a previous study of the effect of IUdR on the growth of
various neoplasms in experimental animals, the Walker carcinosarcoma
256 wee reported not to be affected by this analogue (Jaffe and
Prusoff, i960). Accordingly, it wras of interest to determine
whether the failure to inhibit this tumour is attributable to an
inherent resistance to the inhibitory effects of IUdR, An
horaogenate of this tumour was prepared and the effect of IUdR on the
lit X
utilisation of C-fornate and of H-thymidine for the biosynthesis
of UNA-thymine was investigated. The results (shown in Table 13 and
its histograms) indicate that the biosynthesis of DNA is markedly
inhibited by IUdR. It is pertinent that neither during nor
subsequent to treatment with IUdR were manifestations of toxicity
observed in the rats bearing the Walker carcinosarcoma 236, Thus,
the apparent resistance of this neoplasm to suppression by IUdR in vivo
probably is attributable to an inadequate dosage regimen in this
animal species,
(b) Acute monocytic leukaemia.
In a patient with acute monocytic leukaemia, no benefioial
effect was noted after a 36 hr. intravenous infusion of lUdR, during
96.
Table 13 and acoompanying Histograms.
The effect of IUdk on the utilisation of 3H-thymidine or
C-formate for the biosynthesis of IS?A-thymine by

























* Details of incubation conditions are described in the text.


























which time the subject was given a total dose of 300 mg. of IUdR per
kg. of body weight. ."fter continuous intravenous infusion of IUdR
for 16 hr. sauries of the white blood cells of this patient were
examined in vitro with respect to their ability to utilise thymidine
for the biosyr.thesis of UNI-thymine in the presence of various levels
of IUdRj the results are shown in Table 14 and its histogram). It
is apparent that the extracellular concentrations of IUcLR in this
patient were inadequate to exert any significant inhibitory effect
on the uptake of thymidine since in vitro the addition of
increasing amounts of IUdR resulted in marked inhibition of the
biosynthesis of DIU-thymine. It may be concluded, at least
tentatively, that if an adequate regimen of dosage with IUdR could
be given, which would permit inhibitory concentrations to be attained
under in vivo conditions, inhibition of leukaemio cell proliferation
should be possible. However, such levels of dosage with IUdR
probably could not be administered without causing intolerable effects
on normal cells, particularly those of the bone marrow* Of pertinence,
however, are studies by Calabresi (I96I) which have demonstrated the
feasibility of regional protection with arterially infused thymidine,
given in small amounts (4 to 8 mg./kg,), while IUdR is administered
(110-120 mg/kg.) by intravenous Infusion*
Comparison of kinase activities in various mammalian tissues.
During the course of this study, the kinase activities of
various tissues have been studied. Although no unequivocal
conclusion may be drawn concerning the question as to whether or not
1 i. 'ofnT Tri <3 "tof •
T ^ 'lily uf .hite Hood cell" derived from
patient v\it.i acute monocytic ^euicaemia before and during




























* Details of incubation conditions are described in the text.
° 1 DNA unit is that amount giving same coloured reaction as
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TDP la an intermediate in the conversion of TMP to TTP (Weissaan at al,
1960b} Blanohi at al, 1961), it is of interest that IUdR had no
Influence on the ratio of TCP to TTP* If TCP is an intermediate in
the formation of TTP, then the corresponding phosphorylated
derivative of IUdR, iododeorxyurldine diphosphate, exerts no inhibitory
effect on TCP-kinase• Incubation of acute monocytic leukaemia cells
(Tablet 11 end 12 and related histograms) with radioactive thymidine
or format# resulted in the formation of TCP and TTP in the ratio of
15*1 and 4*1 respectively* This suggest# that if TCP were not en
the direct pathway for the bioayntheaie of TTP, then the latter
compound is uniquely unstable in this cell population* Bianohi
claimed that human tissue contains only small amounts of the ensyme
which phosphozylate thymidine to TMP and that all human tissues convert
TMP completely into TTP in less than 30 mina* The re suite shown in
Tables 10, 11 end 12 do not support these conclusions* For example,
the TMP derived from human acute monocytic leukaemia cells which
were incubated for 2 hr. with %-thymidine represented in two patients
60 and 94 per cent respectively the radioactivity of the combined TMP,
TD? and Ttf! fractions, whereas the TMP fraction derived from -formate
was 50 per cev.t of the combined fractions* A possible explanation for
the differences observed may be that Bianchi derived his conclusions
from studies of particle-free fractions, whereas the present studies
utilised intact cells*
There are many factors which affect the rate of utilisation of
thymidine for the biosynthesis of UNA* Bond et al, 1939 observed
extensive labelling of cells from a patient with chronic myeloid
100.
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leukaemia when they were incubated In vitro with H«*thymidine, but
in chronic lymphocytic leukaemia and myeloma, less than 3 per cent of the
cells took up the ^H-thy nidine. These authors suggested that the
cells with low uptake either have a low turnover rate or lack the
ability to utilise thymidine or have an unusually long DNA-
synthesising time. Moreover, Craddock (i960) found that the uptake
of ^K-thymidine did not correspond with the degree of morphologic
immaturity of the cell population. Thus, in myeloproliferative
disorders the highest degree of labelling was observed in patients
with a low percentage of myeloblasts, while lymphocytes from both
acute and chronic lymphatic leukaemia patients showed a low uptake of
radioactivity, in contrast to the high degree of uptake by normal
thoracic duct lymphocytes. In addition, the uptake was low in two
cases of plasma cell in which a large number of blast cells were
present. In acute myeloblastic leukaemia it was found that 12 per
cent of the cells in the peripheral blood were moderately labelled,
a circumstance which indicated that although many cells were
synthesising DMA, the rate per cell was quite slow. That too close
a correlation should not be drawn between the distribution of radio¬
activity in the three nucleotide fractions and the rate of DNA
synthesis can be seen from later experiments (p.116-123 ) since the
percentage of total radioactivity present in each fraction varies
depending upon the length of inoubation.
Mechanism of action of 5-lodo-2l-deoxyuridine.
Thymidine monophosphate Is the initial compound common to (a)
the de novo pathway for the biosynthesis of the thymine-component of
101.
DKA, via 2' -deoxyurldylic Mid and (to) the exogenous psthwqr, *toioh !•
oonce roed with the utilisation of thymidine derived either from
dietary sources, or from the degradation of DNA, or from toiosynthetio
reactions of other cells or tissues. The appropriate kinases
subsequently catalyses the phosphorylation of TMP to TEP and TTP,
prior to polymerisation into MA (Bessaan at al, 1958aj Bollum and
Potter, 1950b. and 1959) Canellakis and Mantsovanos, 1953) Lehman et
al, 1956) Canellakis et al, 1959)* It nay toe inferred that lUdfi
is converted to the corresponding mono-* di and tri- phosphates,
since IUdR has been shown to tot incorporated into BRA (Prusoff, 1959b
and 1960b, Mathias and Fischer, 1959a) fiathias et al, 1959b| Jaffa end
Prusoff, 196O) Cheong et el, I960) lldinoff et el, 1959o, d, and a) by
replacement of TMP. Inhibition of a specific kinase probably is
mediated by the appropriate phoaphorylated analogue, e.g. TMP toy
5-iodo~2'-deoxyuridine 5'-monophosphate (lUdE-S'-P)* This relation-
ahip is depicted in Figure 7. Thus, the utilisation of thymidine
or of formate for the toloayntheals of EKA-thymine fey mouse 151761
leukeemie eells la toloeked fey the appropriate derivative of lUdft
primarily at the thymidine kinase (reaction 1) and thyaidylio aoid
kinase (reaotion 2) respectively; whereas the utilisation of these
precursors for the toiosyntheeie of DNA-thymine in mouse Shrlioh aseitea
cells is blocked at a tingle site, DHA-polymerase (reMtioa 5). It
is of interest that inhibition of the conversion of TDP to TTP waa
not observed in any of the tissuea investigated.
An unexpected observation was the decreased formation of
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Metabolic interrelationship of IUDR and precursors
of DNA-thymine
the inhibition of the thymidilate synthetase reaction.
The inhibitory effect of XUdti (or more probably its
phosphorylated derivatives) is therefore exerted at specific metabolic
reaction sites, the primary site being related to the nature of the
precursor as well as the species of cell.
SUMMARY.
A study has been made of the effect of IUdR on the formation
and utilisation of phosphorylated derivatives of thymidine, as well as
on the formation of UNA-thymine, in various murine and human neoplastic
103*
tissues. The decreased incorporation, in the presence of IUdR, of
lit- 3
the incorporation of C-forunte and thymidine into DNA-thymine
is a reflection of an inhibition of the utilisation of thymidine,
thymidylic acid or thymidine triphosphate, presumably by IUdR or the
corresponding phosphoiyl^ted derivatives of IUdR, It is to be noted
that the specific metabolic site primarily affected in the various
tissues studied is a characteristic of the individual tissue. Thus,
DNA-polyraerase was primarily inhibited in murine hhrlioh ascites
carcinoma and in human chronic granulocytic and acute monocytic
leukaemias, whereas studies with murine L517SY leukaemia cells,
using thymidine and ^C-formate showed a primary blockade of
thymidine kinase and thymidylic acid kinase, respectively.
Confirmation of the inhibition of thymidine kinase was obtained with
a cell-free extract of the L5178Y cells. With normal calf thymus,
thymidylic acid kinase, but not thymidine kinase, was inhibited
primarily. The apparent resistance to TUcLR of the Walker
carcinosarcoma 256 of the rat, in vivo, as well as of a patient with
acute monocytic leukaemia, could be explained by an inadequate dosage
regimen, since marked inhibition of the biosynthesis of UNA by these
tissues could be demonstrated in vitro.
104.
SECTION II.
COMPARATIVE STUDIES WITH S-IODO-a'-DEOXYURIDINE AND 5-IQD0-2'-DEOXYCYTIDINE.
Introduction;
With the advent of ICdR it was important to compare its
effectiveness with IUdR as a thymidine antagonist both by in vitro
1°- vivo studies and to determine whether or not it offered
significant advantages over the uracil derivative. It was hoped
that ICdR might show greater metabolic stability (Verdier and
Potter, i960) thus enabling a greater concentration of the drug
to be incorporated into the DNA of proliferating cells. Moreover,
the presence of the enzyme de oxycytidylate deaminase in certain
neoplastic tissues and its absence from most normal tissues offered
the possibility of the preferential utilisation of ICdR by malignant
cells. Unfortunately, the results shown below do not substantiate these
hopes and suggest that certain normal tissues do deaminate ICdR and
that certain neoplastic cells do not. For example, the following
results show that ICdR is much less effective than IUdR as an inhibitor
of the synthesis of DNA-thymine by mouse lymphoma L5178Y cells
in vitro but in vivo it is only slightly less effective as an
inhibitor of tumour growth suggesting that in this instance the
pxlor deamination by some other tissue or organ (such as the liver
or kidney) is essential before maximum therapeutic efficiency is
obtained.
Effect of lUdR and ICdR 011 the growth of Streptococcus faecalis (ATCC 8045)
Organisms were grown in a medium in which the limiting factor
105.
was thymine, thymidine or folio acid, this metabolite belng present
in sufficient concentration to allow half maximum growth in each
instance. The effect of the analogue to compete with these
metabolites was tested by the addition of the analogue in increasing
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It will be readily appreciated that while IUdP caused increasing
inhibition with increasing concentration, IC&K did not, There was,
however, a reproducible slight inhibition of growth when ICdK was
added in a concentration of 2 yuaoles/tnl. to the medium in which
thymidine was the limiting growth factor.
The reason for the failure of ICdK to Inhibit growth was not
investigated but the most likely explanation is that the organisms were
unable to deamlnat© the analogue to the corresponding uracil
derivatives. Other possibilities such as failure of transport
into the cell cannot be excluded.
Effect of IUdh and ICdk on the growth of the solid tumour form of mouse
lymphoma L5178Y in vivo.
Experiments were performed in mice at two different dosage schedules
for each drug. The capacity of each drug to inhibit the growth of the
tumour was estimated using the method described on p.72. The results
are shown in Table 15, From these results it would appear that ICdii is
slightly less inhibitory than lUdk, the percentage tumour inhibition at the
9 pi. dose level being 60 per cent and 78 per cent respectively# There
was also leas toxicity than with IUdR but it has previously been shown
that IUdk may be used in this dosage without giving rise to any
mortality (Jaffe and Prusoff, 19&Q)• It has since been reported,
however, that in acute and chronic toxicity studies in mice, ICdil is
less toxic than Ilidh (Cramer ©t al, 1962)#
Effect of ItldK and ICdh on the biosynthesis of the phosphorylated
derivatives of thymine and INA-thymine.
(a) Ehriioh Ascites Carcinoma Cells in vitro.
109.
Table 15.
The effect of IUdA and. ICdR on the growth of the solid
tumour form mouse lymphoma L5178I in vivo.
Drug Dosage Level Average Change Mortality Average Approx. %
pm/iaouse/day Body weight Tumour Inhibition.
Weight
IUdR 9 - 2.0 Vio 50 78
3 + 0.8 2/l0 134 41
ICdR 18 - 2.4 °/10 31 97
9 - 1.6 °/10 91 60
Control — + 0.6 °/10 226 -
110.
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1. With H-thymidine as the precursor:
The results shown in Table 16 and its accompanying histogram
indicate that ICdR is less effective than lUdR as an inhibitor of the
biosynthesis of ENA-thymine; the inhibition produced by ICdR being
only 55 per cent while that due to IUdR wa3 87 per cent. Neither
drug appeared to inhibit the biosynthesis of the nucleotide fractions
suggesting that in both cases the primary site of inhibition was at
the polymerase stage. It is of interest, however, that the
accumulation of radioactivity in the nucleotide pools behind the
site of metabolic inhibition was considerably greater in the case of
ICdR than IUdR, The total radioactivity in the nucleotide pools
was increased by 40 per cent over that in the control cell3 in the
case of IUdR and 80 per cent in the case of ICdR.
Effect of IUdR and ICdli on the biosynthesis of ENA-thymine.
(a) Mouse lymphoma L5178Y cells in vitro.
1. With ^H-thymidine as the precursor -
In Table 17 and the associated histogram are shown the results
obtained from a 2 hours incubation of lymphoma L5178Y cells in vitro
with IUdR and ICdR. It can be readily seen that ICdR under these
conditions is muoh less effective than IUdR as an inhibitor of DNA-
thymine, the percentage inhibition being approximately 38 and 97
respectively.
When ^C-formate waa used as the precursor the results were
very similar to those with thymidine as the precursor (Table 18 and
its histogram). In a further experiment in which the cells were
Ill
Table 16 end accompanying: Histogram*
Effect of IUcLR and ICdR on the utilisation of ^H-thymidine
for the biosynthesis of TMP, TDP, TTP and DNA-thymine by
Ehrlich ascites cells in vitro.
Analogue TMP TDP TTP DNA-thymine
cpm/unit DNA
None 5500 4500 3300 55,500
IUdH 6500 5250 6750 7200
ICdtt 8000 9250 8750 25,200
°cpm in amount of DNA corresponding to 1 mg. thymidine in
the Stumpf reaction.
112
Table 17 and accompanying Histogram.
Effect of IUdfi and IC&R on the utilisation of thymidine
for the biosynthesis of DNA-thyaine by mouse lymphoma







cpm in amount of MA corresponding to 1 tag. thymidine
in the Btuinpf reaction.
DNA-T
113.
Table 18 and accompanying Histogram.
Effect of lUdH and ICdR on the utilisation of C-fornate
for the biosynthesis of DNA-thymine in mouse lymphoma
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older ana less active metabolically there was no evidence at all
of inhibition of the synthesis of DNA-thymine by ICdH.
The relative inefficiency of ICdR compared with IUdK as an
inhibitor of the synthesis of the phosphorylated derivatives of
thymidine and DNA-thymine may indicate that the cells were lacking
in the appropriate deaminase or that ICdR did not penetrate into the
cell. The greater inhibitory effects observed with the compound in
in vivo studies suggest that the compound may be deaminated elsewhere
in the body e.g. in the liver or kidney, and subsequently acts as
ItJdfi. at the tumour site.
These initial studies suggest that weight for weight ICdR is
less effective as an inhibitor of the synthesis of the thymine
nucleotides and DNA-thymine than IUdll. The decreased toxicity,
however, the increased solubility in water, and higher resistance
to thermal decomposition in water of ICdR, in comparison with IUdR,
offer significant advantages of this compound in the treatment of
neoplastic disease.
SUMMARY.
Comparative studies have been made of the biological activities
of IUdR and ICcLK, The utilisation of ^H-thymidine and ^C-formate
for the biosynthesis of DNA-thymine of L5178Y and Ehrlich ascites
tumour cells in vitro is inhibited markedly by IUdR but to a much
lesser degree by ICdR, Similarly the growth of Streptococcus faecalis
115.
is inhibited markedly by IUdit but not at al by ICdR.
The growth of L5178Y lymphoma in rlvo. however, is inhibited




EFFECT OF DSQXYCYTIDINE ON THE E/TE OF BIOSYNTHESIS OF PHOSPKORYLATSP
DERIVATIVES OF THYMIDINE AND DN/."THYMINE.
Introductiont
The utilisation of radioactive formate for the biosynthesis
of the methyl group of DMA-thymine by mammalian cells in vitro has
been shown to be increased by the nucleosides of uracil and cytosine,
tne latter having greater effectiveness (Pruaoff, 1958a). It has been
established in cell free systems that deoxyuridylio acid ia an
acceptor of the single carbon unit during the formation of IMP
(Phear and Greenberg, 1957)* Since both the riboside and
aaoxyriboside of cytosin© were more stimulatory than the corresponding
nucleosides of uracil, tne possibility of the cytosine derivatives being
an acceptor of the single carbon unit in addition to that of uracil
was entertained (Pruaoff, 1958a). The existence of 5~®ethyl cytosine
derivatives in INA (Wyatt, 1951a), as well as of a methyl cytosine
deaminase (Wyatt, 1951b) was offered in support of this hypothesis.
Biochemical evidence has since been reported of the greater stability
of the cytosine nucleoside in comparison to the corresponding uracil
derivative to metabolic degradation (Krlss ana neves, 1962) and hence
toe possibility of the greater effectiveness of the cytosine
nucleosides merely by supplying a more stable depot of dUMP for
condensation with tine single carbon unit oust also be considered in
explanation of the results reported previously. An investigation
has baen made of the effaot of deoxycytidine on the formation of IMP
117.
TDP, TTP and DNA-thymine.
Time studies on the effect of Deoxycytidlne on the utiliaation of
formate for the biosynthesis of the phosphorylated derivatives of
thymidine end IJNA-thymine.
Murine lymphoblastic leukaemia I.5178Y cells were harvested
6 days following the innoculation of MR x DBA/2 P^-hybrid mice.
The cells were prepared and incubated as described under
methods (p.60-62). The results obtained are depicted in Figures 11,
12, 13 and 14. Figures 11 and 12 represent an experiment in which the
cells were first examined after 5 mins. and Figures 13 and 14 represent
a similar experiment in which samples were taken from 0.5 mins. onwards.
The striking feature is that within 1 min. of incubation in the
presence of deoxycytidine a marked increase was observed in the various
thymine nucleotide fractions over those in the control cells. Also
the TMP fraction within this period of time contained most of the
radioactivity delived from formate. This is in agreement with the
concept that formylation occurs at the nucleoside monophosphate level.
These results do not present evidence in support of an acceptor role
for deoxyuridylic acid to the exclusion of deoxycytidylic acid.
Deoxycytidine presumably following phosphorylation could accept the
single carbon unit and then become deaminated, whereas the accepted
pathway for which evidence is available would suggest that following
phosphorylation, deamination by deoxycytidylic deaminase occurs prior
to the acceptance of the single carbon moiety. The data presented
are in agreement with either interpretation and until evidence is














Diagram showing total radioactivity in each of the thymine nucleotide
fractions following incubation of mouse lymphoma LS178Y cells with























Diagram showing total radioactivity in each of the thymine nucleotide
fractions following incubation of mouse lymphoma L5178Y cells with
C-formate and deoxycytidine for increasing periods of time




Diagram showing total radioactivity in each of the thymine nucleotide
fraotions following incubation of mouse lymphoma L5178Y cells with




Diagram showing total radioactivity in each of the thymine nucleotide
fractions following incubation of mouse lymphoma L5178Y cells with
■^-formate and deoxycytidine for increasing periods of time
beginning from 0.5 tains.
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nucleotide intermediate, it must be assumed that deoxyoytidine exerts
its stimulatory effect via deoxyuridylic acid and not via a formylated
cytosine intermediate.
Although the distribution of radioactivity in the TMP, TIP and
TTP fractions derived from cells incubated in the presence and absenoe
of deoxycytidine at the various intervals of the time studied were
essentially similar, there was a marked increase in the absolute amount
of radioactivity when incubated with deoxycytidine.
Prom Figures 13 and 14 may he seen that there are two dips in
each of the curves. The first occurs at approximately the same point
in time in each fraction (i.e. at about 1 minute) and there are
several possible explanations. It might be related to the beginning
of DNA synthesis which may possibly have been delayed due to previous
oooling of the cells or some other unknown factor. If this were so,
it would probably be necessary to postulate the formation of
oligonucleotides which were present in the acid soluble fraction
but possessed of too strong a charge to be eluted from the column
along with the TIT fraction.
The second dip in the curve occurred in all instances after
30 minutes and here the explanation is equally difficult. From
Figure 15 in which the total radioactivity in the three fractions
(TMP, TDP and TTP) is plotted against time it is clearly demonstrated
that the rate of formation or accumulation of nucleotides drops
precipitously after 16 minutes and probably indicates that catabolic
reactions are playing a large part in determining the distribution of
radioactivity. Since DNA is still being synthesised at the same time,
123.
Figure 15.
RATE OF INCREASE OF RADIOACTIVITY IN THE TOTAL
THYMINE NUCLEOTIDES FOLLOWING INCUBATION OF
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(Table 19, Fig. 16), the interpretation becomes very difficult.
In Figure 17 the percentage of the total radioactivity in each
fraction is plotted as a function of time during the first 16 minutes.
It may be noted that the TMP and TTP curves are roughly reciprocal. As
the percentage radioactivity falls in the TMP fraction it rises in the
TTP fraction suggesting the possibility of the conversion of T?£P to
TTP without the formation of TDP. Moreover, the rise in radioactivity
in the TDP fraction coincides with a decrease in the TTP fraction. Both
of these phenomena are consistent with the suggestion of Bianchi
that TMP is converted to TTP with the subsequent production of TDP
by dephosphorylation of TTP. Whether TDP is actually on the metabolic
pathway or not can only be determined by the measurement of the specific
activity of the nucleotide fractions.
Effect of deoyyyytidine on the capacity of IUcLR to Inhibit the
utilisation of C-formate for the biosynthesis of the phosphorylated
derivative of thymidine and DNA-thymine.
It has already been shown that lUdR markedly inhibited the
utilisation of ^'+C-forraate for the formation of TMP, TDP, TTP and
DNA-thymine in the L5178Y cells in vitro (p. 81). In view of the
increased formation of thymine nucleotides in the presence of
deoxycytidine, it was of interest to determine whether deoxycytidine
could reverse the inhibitory effects of IU&R. In these cells the
prime metabolic site of inhibition had been shown previously and
confirmed here to be in the conversion of Tiff to higher phosphorylated
nucleotides. The results are shown in Table 20 and its histogram.
Again lUdfi. resulted in a small but definite decrease in the
125.
Table 19 and Figure 16.
The effect of deoxycytidine on the utilisation of radioactive
formate for the biosynthesis of DNA-thymine by murine lymphoma
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Table 20 end accompanying Histogram,
Effect ol aeoxycytidine on the inhibition by lUdrt of the
utilisation of G-formate for the biosynthesis of TI£P,
TDP, Til and thymine by mouse leukaemia 5178 in vitro
Addition Tr.'P TDP TIP
cpis. cpm. cpm.
None 2900 5900 12,400
IUdR (5 p.) 1900 680 1,800
CdR (10 p.) 6500 29,000 66,000






























amount of TT f .1 wd in the presence or absence of deo^cytidine, but
o more markad inhibition in the formation of the higher phosphorylated
thymine nucleotide3 (TLP end TTP). The inclusion of lUdR, in the
presence or absence of dsoxycytidine, resulted in approximately 75
per oent inhibition in the specific activity of INA-thymine. However,
the absolute specific activity of CIIA~thymine as well ©s the
individual nucleotide pocla derived from cells incubated in the
presence of lUdP. end deoxycytidine were markedly higher than those
derived from the non-inhibited cells incubated in the absence of
deoxycytidine. Thus, deoxycytidine did prevent in part the inhibitory
effects of lUdit, presumably by increasing the aire of the TKP pool.
it.' :i.
A study has been made on the effect of deoxycytidine on the
biosynthesis of the phosphorylated derivatives of thymidine and TNA-
thymine in murine lymphoma 15-17^' cells in vitro. In each of these
fractions the amount of ^C-foraate incorporated was increased
approximately two to three fold in the presence of deoxycytidine at
all intervals of time up to a 4 hour incubation period. Although no
conclusive results can be drawn an ©nalysis of the amount and
distribution of radioactivity In the various fractions at intervals of
0.5 rains, to 4 hrs. suggests that TMP is formed from dUM? and then
converted directly to TTP without the intervention of TCP which may be
formed later by dephosphoxylation of TTP. Deoxycytidine has again
been shown to be a precursor of 1HA-thymine and T&P appears to be the
primary product, but whether denial nation occurs before or after
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methylation is undetermined. The pattern of inhibition of the
synthesis of the thymine nuoleotides produced by IUdR was not
altered by deoxycytidine but the absolute inhibitory effects were




In order to assess the clinical value of IUdR and ICdR in
the chemotherapy of neoplastic disease much more experience with the
compounds is needed. Both drugs are extremely expensive, however,
and the supply is consequently very restricted at the moment*
Three major clinical aspects may be considered in the
evaluation of the potential effectiveness of an antimetabolite, the
use of the drug alone, the use of the agent in combination with
radiotherapy and combination therapy with other suitable antimetabolites.
In the light of its biochemical activity, IUdR offers possibilities
in all three directions. It is capable of blocking an important
metabolic pathway and of actually altering the composition of the
DNA, This not only causes the death of some cells but also gives
rise to increased sensitivity to radiation injury. Finally, the
synergistic inhibition of both the biosynthesis de novo of TMP and
its incorporation into DNA through the use of a combination of FUdR
and IUdR has aroused great interest.
Although IUdR is extensively incorporated into the DNA polymer,
it has not been established that inhibition of cellular reproduction is
causally related to this observed effect. The decrease in the
biosynthesis in thymine nucleotide fractions consequent upon
administration of IUdR may be of relevance. Many pyrimidine
nucleotides are known to function as co-enzymes but no such role has
so far been shown to exist for the thymine nucleotides in mammalian
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cells. That such functions do exist, however, cannot be excluded
particularly in view of the fact that they have been implicated in
the synthesis of the bacterial cell wall (Okazaki, I96O; Kornfeldt
and G-lasor, i960). ICdE following deamination, appears to act in
a manner similar to lUcLR but whether or not it has, in addition,
other actions which are peculiar to the cytidine derivative is as
yet undetermined.
The effects of IUdR appear- to be exerted on rapidly growing
tissues of all kinds and so far not enough difference has been noted
between its inhibitory action in normal and neoplastic cells to produce
the desired results. In view of the reports of higher levels of
dCMP-deaminase activity in certain experimental tumours (Maley et al,
1959) as compared with normal tissues, however, ICdR may hold out more
hope for a selective attack upon neoplastic tissue, since it may be
preferentially phosphorylated and deaminated by these malignant cells.
This hope was not borne out in the experiments reported above but this
does not exclude the possibility of such an effect with certain tumours
in man.
Although only very preliminary studies have been made on the
extent of uptake of IUdR into UNA of human tumours, it appears that
under the dosage regime so far employed only very small amounts have
been incorporated (Welch, I96I). This is probably to be expected
since not more than about one third of the cells are synthesising
UNA at any one time and the exposure of these cells to IUdR has been
only for a few hours. Higher levels of incorporation might be
obtained if the drug were administered slowly over long periods of
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time, particularly if given intra-arterially in the particular vessel
supplying the neoplasm. .Yhether increased incorporation of the drug
would, in fact, enhance its effectiveness as an antitumour agent, still
has to be proved.
Of great interest is the capacity of at least some of the
halogenated pyrimidines to sensitise cells to *-irradiation. The
clinical usefulness of these compounds Is that differential
radiosensitisatlon of neoplasm might be achieved by coupling the
selective affinity of such agents for dividing cells with localised
irradiation which would thus confine the enhanced effect to the
treatment field and spare normal rapidly dividing tissue such as
marrow and intestine (Djordjevlc and Szybalski, I960). As Kaplan
et al (1962) point out, however, if "bifilar" labelling of UNA is
really essential for radlosensitivity to occur then the tumour would
have to be allowed to double in sise and then replicate its DNA once
more in preparation for doubling again in the presence of the analogue
before the radiosenaitivity of any of its cells would be significantly
enhanced. Fortunately, the necessity of "bifilar" labelling has
been seriously challenged so that the possibility of combination
therapy with X-rays serving as a useful clinical tool still remains,
as some of the in vivo studies already carried out would suggest#
An approach to combination therapy which these authors suggest
is the alternate use of the analogues and irradiation. These
procedures, if spaced at optimum intervals, could label end then
selectively destroy a small proportion of tumour cells at each cycle
leaving behind the more radioresistant cells to be labelled in a
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sub30quent cycle. If such ari approach enabled complete sterilisation
of the tumour with as little as a 10 per cent reduction in total dose
of X-rays it would represent a very real advance, since the margin
of safety in many radiotherapeutic situations is small,
Whether or not an effective agent for the control of cancer
will be found, it is certain that through continued studies of the
metabolic reactions affected by the agents under discussion and others
like them, important contribution will be made to our knowledge of the
fundamental processes of the cell, both normal and neoplastic. Moreover,
other uses will no doubt b® found for certain of them other than that
for which they were originally designed. It has recently boon
demonstrated (Kaufman, 1962; Perkins ®t al, 1962; Corrigan et al, 1962)
that IUdR when administered locally is effective against the virus of
herpes simplex as it affects the eye. Such infections are extremely
difficult to treat and may lead to corneal scarring and blindness. If,
therefore, these claims are substantiated by future workers, lUdR will
be an exceedingly valuable drug and one of the few which has any action
at all on virus infections.
the most rational approach to chemotherapy would appear to
be based on an essential biochemical difference of a quantitative
nature between neoplastic cells and their normal counterparts. One
of the best examples of audi an approach is the marked suocess achieved
with the sulphonamide compounds which inhibit the biosynthesis of folle
acid by certain microorganisms by competing with para-aminobensolo
acid for essential ensyraes. The mammalian host meanwhile is unaffected
because, unlike the microorganisms, it is capable of utilising preformed
folic aold ingested in the food for participation in various metabolic
reactions. Unfortunately, analogous quantitative differences have
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not so far been found in neoplastic cells as compared with normal
cells. However, it is doubtful whether new chemical reactions would
be expected to appear in the probable conversion of e normal cell to
a neoplastic one. It would appear to be more probable toat certain
biochemical f© tuxes are deleted and that such cells no longer respond
to their environmental controlling influences in the same way as the
normal cell. Quantitative differences, however, are seen in some
tumours as compared with normal tissues. One such example is the
ability of certain tumours to carry on aerobic as well as anaerobic
glycolysis at sustained high levels with the production of large
amounts of lactic acid from glucose.
In future cancer research toe biochemistry of toe malignant
cell in humans is worthy of much more investigation. If
characteristic metabolic pathways can be elucidated it may be possible
to design compounds with a specific action. In this event each type
of tumour could be treated with the drug best able to interfere with
the particular biochemical reactions concerned.
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SUMMARY OF THESIS.
The biosynthesis of the phosphorylate a derivatives of
thymidine and of DNA-thymine has been reviewed. The compounds
which interfere with specific reactions on the metabolic pathways
concerned have been discussed and particular attention drawn to
the halogensted pyrimidines which behave as analogues of uracil
or thymine or their derivatives. Such compounds inhibit the
synthesis of UNA-thymine and in consequence DHA-synthesis and
cellular reproduction is often impaired. The helogenated pyrimidines
may themselves be incorporated into DMA in lieu of thymine with the
formation of fraudulent DM and in the cells concerned a reduction
in the threshold of radiation sensitivity may ensue. The available
information on the clinical effects of the halogensted pyrimidines
both on tumour growth and on radiation sensitivity has been
summarised.
Studies on the thymidine analogues 5-iodo-2'-deoxyuridine
(lUdh) and 5-iodo-2'-deoxycytidine (ICdh) have been described.
Investigations were undertaken to determine the effect of these
analogues on the formation and utilisation of the phosphorylated
derivatives of thymidine and on the formation of UNA-thymine in
various murine and human neoplastic tissues. Both compounds
reduced the incorporation of thymidine or ^-formate into
UNA-thymine as a result of the inhibition of the utilisation of
thymidine, thymidylie sold or thymidine triphosphate and the specifie
1}6.
metabolic site primarily affected in the various tissue studied was a
characteristic of the individual tissue.
Comparative studies with IUdR and ICdft were undertaken both
in vitro and in vivo. The mechanism of action of ICdR (following
deamination) was found to be similar to that of IUdR but it appeared
to be less effective as an inhibitor of the synthesis of DNA-thymine
and it had little or no effect on the growth of Streptococcus faecalls,
an organism whose growth is severely inhibited by IUdR, In mice,
however, the compound was only slightly less effective than IUdR in
the inhibition of tumour growth, in vivo.
The effect of deoxycytidine on the biosynthesis of the
phosphorylated derivatives of thymidine and DMA-thymine has also been
i
studied in murine lymphoma L5178Y cells in vitro. In each of these
fractions the amount of ^C-formate incorporated was increased two to
three fold in the presence of deoxycytidine. Although no conclusive
results could be drawn on analysis of the amount and distribution of
radioactivity in the various fractions after periods of incubation
which varied from 0.5 mins. to A hours, it appeared that deoaycytidine
increased the rate of formation of thymidylic acid which was then
converted directly to thymidine triphosphate without the intervention
of thymidine diphosphate which may be formed later by dfephosphorylation
of the triphosphate.
Deoxycytidine was shown to reduce the inhibitory effects of
IUdR on the biosynthesis of the thymine nucleotides and DNA-thymine.
A brief discussion is given on the antimetabolites under study
with suggestions for their possible clinical application in the future.
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